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Therapeutic strategies targeting FUS toxicity in amyotrophic lateral sclerosis: from a novel 
mouse model of disease to a first-in-human study 
Vladislav Korobeynikov 
 
 Fused in sarcoma (FUS) is an RNA binding protein involved in DNA repair and RNA 
metabolism, including mRNA transcription, splicing, transport and translation. FUS is genetically 
and pathologically associated with rare and aggressive forms of amyotrophic lateral sclerosis 
(ALS) and frontotemporal dementia (FTD). To explore the mechanisms by which pathogenic 
mutations in FUS cause neurodegeneration in ALS-FUS, we generated a series of FUS knock-in 
mouse lines that express the equivalent of the ALS-associated mutant proteins FUSP525L and 
FUSΔEX14 at physiological levels from the FUS locus. We demonstrate that heterozygous mutant 
FUS mice show progressive, age-dependent loss of vulnerable subpopulations of spinal motor 
neurons. While ALS-associated mutations in FUS lead to partial loss of function, we provide 
genetic evidence that the motor neuron phenotype observed is a consequence of a dose-dependent 
gain of function, associated with the insolubility of FUS and related RNA binding proteins (RBPs). 
Furthermore, we show that motor neuron degeneration is driven by cell autonomous mechanisms, 
associated with mutant FUS-independent inflammatory changes. In this faithful mouse model of 
ALS-FUS, we demonstrate that an antisense oligonucleotide (ASO) targeting the FUS transcript 
 
 
(ION363) results in the efficient silencing of both wild type and mutant FUS alleles, and that 
postnatal reduction of FUS protein levels in the brain and spinal cord delays disease onset in this 
mouse model of ALS-FUS. In a first-in-human trial of ION363, we demonstrate that repeated, 
intrathecal injections of this candidate therapeutic in an ALS patient with a FUSP525L mutation 
leads to the efficient silencing of both wild type and mutant FUS in the central nervous system, 
and a reduction in the burden of FUS aggregates that are a pathological hallmark of ALS-FUS. In 
mouse genetic and human clinical studies, we provide evidence in support of a therapeutic strategy 
by which silencing of the FUS gene may be used to prevent or delay disease onset in pre-
symptomatic carriers of pathogenic FUS mutations, or to slow disease progression in symptomatic 
ALS- and FTD-FUS patients. In addition, we use this newly generated model to investigate the 
role of potential modifiers of FUS toxicity, including hnRNP U and UPF1, and study the role of 
chronic neuroinflammation in the disease progression that could lead to the development of novel 
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Amyotrophic lateral sclerosis (ALS) is a fatal neurological disorder characterized primarily 
by the degeneration of corticospinal, bulbar and spinal motor neurons, leading to paralysis and 
death1. ALS typically presents as an adult-onset progressive muscle weakness with features of 
simultaneous involvement of both upper (hypertonia, hyperreflexia, and pathological reflexes) and 
lower (hypotonia, hyporeflexia, and fasciculations) motor neurons. Many patients also develop 
additional cognitive and behavioral changes characteristic of frontotemporal dementia (FTD)2 due 
to shared molecular mechanisms underlying both disorders3,4. The age of onset is typically over 
60 and most patients die within 3-5 years after symptom onset due to respiratory failure. 
ALS is considered the most common disease affecting motor neurons (MNs) with the 
prevalence of 5 per 100,000 in the United States5 and estimated incidence averaging at 1,6-2 per 
100,000 per year in Europe6 and North America7-9.  
 
Genetics of ALS 
While most cases are sporadic, up to 10% of ALS cases have clear family history of ALS 
or FTD. In familial forms of the disease and a significant proportion of sporadic cases, ALS can 
be caused by a mutation in a number of genes. SOD1, Cu/Zn superoxide dismutase, was the first 
gene to be linked to ALS in 199310. In recent years, with the development and widespread 
implementation of next-generation sequencing techniques, more genes have been reported to be 
associated with ALS11,12. Pathogenic mutations have been identified in over 25 genes, however, 
they only account for approximately 15 percent of all cases of ALS13-16. There is a growing 
evidence suggesting oligogenic etiology of ALS with numerous genetic variants contributing to 
the risk of developing the disease17, however, those remain elusive. 
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The genetic complexity of ALS underlies wide phenotypic variability in the motor neuron 
phenotype in terms of the age and site of disease onset, the balance of upper and lower motor 
neuron findings, and the rate of disease progression.  
 
SOD1 
Mutations in SOD1 gene are responsible for ~20% of familial ALS cases with a higher 
prevalence in Asian population (~30%) in comparison to Europeans (~15%); in sporadic ALS 
cases, SOD1 mutations could be found in less than 2% of cases16. 
SOD1 is 153 amino acids long metalloenzyme containing Cu/Zn and forming a stable 
homodimer. It is ubiquitously expressed and found in cytosol of the cells and mitochondrial 
intermembrane space. It catalyzes the conversion of superoxide produced during cellular 
respiration to oxygen and hydrogen peroxide18. Although some ALS-associated SOD1 mutations 
were reported to decrease its enzymatic activity10,19, there is no correlation between the degree of 
functional impairment of the protein and the disease severity20. In addition, SOD1 knockout mice 
were reported to have no MN pathology21 suggesting that SOD1 loss of function is unlikely to 
cause neurodegeneration. ALS-associated SOD1 mutations are considered to cause the disease 
through a variety of possible gain-of-toxicity mechanisms, including oxidative stress, ER stress, 
mitochondrial dysfunction, axonal trafficking defects, non-cell-autonomous glial toxicity, and 
prion-like propagation22.  
Over 185 mutations throughout the SOD1 gene have been reported23 with D90A being the 
most common mutation worldwide and A4V in the US. Some SOD1 mutations, i.e., H46R24, have 
been reported to have a remarkably uniform clinical phenotype while clinical presentation of other 
mutations can have a high degree of variability. However, most SOD1 mutations have been 
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reported to have autosomal dominant hereditability and clinical presentation with predominant 
lower MN involvement. 
Neuropathologically, SOD1 cases are characterized by the presence of Lewy body-like 
inclusions on H&E stain that represent SOD1- and ubiquitin-immunoreactive aggregates that can 
also contain other proteins including phosphorylated neurofilament25 and 14-3-3 protein26. 
Monoclonal SOD1 antibodies to certain epitopes can detect misfolded protein in spinal motor 
neurons of ALS-SOD1 patients, however, Betz cells in the motor cortex usually do not contain 
misfolded SOD1. These neuropathological features are unique to ALS cases caused by SOD1 
mutations as virtually all other cases except for ALS-FUS show distinct TDP-43 pathology27. 
Notably, some reports suggest the presence of misfolded SOD1 protein in tissues from sporadic 
ALS patients based on immunostaining28,29, however, the extent of this contribution to the disease 
mechanism remains unclear and these findings themselves remain controversial30,31. 
These observations strongly suggest distinct molecular mechanisms underlying the disease 
pathology in SOD1 and question the applicability of research involving transgenic SOD1 G93A 
mice, the most used ALS model32, to the broader population of patients with non-SOD1 ALS. This 




In 2006, TDP-43 (TAR DNA-binding protein 43) was discovered as the major component 
of ubiquitin-positive tau-negative inclusions in sporadic ALS and a subset of FTD cases33,34 and 
shortly after several mutations in TARDBP gene encoding TDP-43 protein were linked to ALS35,36. 
Subsequently TDP-43 pathology was found in most non-SOD1 ALS cases27 including C9orf72 
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cases37. The presence of distinct skein-like TDP-43 aggregates and diffuse cytoplasmic TDP-43 
immunoreactivity in neurons is now considered a pathological hallmark of ALS and FTD-TDP38. 
TDP-43 is a ubiquitously expressed DNA/RNA-binding protein that regulates most aspects 
of RNA metabolism, including control of gene expression, regulation of pre-mRNA splicing, 
mRNA stability, transport, and translation39. TDP-43 is critical for embryonic development40 and 
motor function: both heterozygous TDP-43 knockout mice40 and mice with MN-specific TDP-43 
elimination41 develop motor abnormalities, however, no motor neuron loss was observed in either 
model. Transgenic models overexpressing WT or mutant TDP-43 provided evidence supporting 
gain-of-toxicity mechanism of TDP-43 toxicity42-44. 
TDP-43 mutations are responsible for around 4% of familial and less than 1% of sporadic 
ALS cases. Most mutations occur in the C-terminal glycine-rich low complexity domain that is 
highly conserved. This prion-like domain45 is required for multiple protein-protein interactions46 
and involved in liquid-liquid phase separation, aggregation, and prion-like propagation. ALS-
associated mutations in TDP-43 were reported to significantly affect these properties of the 
protein47,48 suggesting that is the main mechanism of TDP-43 toxicity. 
 
C9orf72 
Expansion of G4C2 hexanucleotide repeats in the intronic region of C9orf72 gene was 
linked to ALS and FTD in 2011 by two independent studies49,50. Healthy controls typically have 
5-10 repeats while ALS or FTD patients can have up to several thousands of repeats. The length 
of the repeats does not correlate with the age of onset or severity of the disease51. C9orf72 
hexanucleotide repeats expansion (HRE) is the most common genetic mutation causing both 
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familial and sporadic ALS in European population; however, it is almost absent in Asian 
population16,52. 
On neuropathological examination, all C9orf72 cases have cytoplasmic TDP-43-positive 
inclusions and are classified as TDP-43 proteinopathies. However, a unique feature of C9orf72 
pathology is the presence of p62-positive TDP-43-negative aggregates that include dipeptide 
repeats (DPRs)53,54 accumulating in various brain regions. Another defining characteristic is the 
presence of RNA foci55. Interestingly, RNA foci accumulate in cells with high a degree of TDP-
43 proteinopathy56. 
The function of C9orf72 gene product is not known; it is suggested to be involved in 
autophagy57, endosomal trafficking58, and immune system regulation59,60. However, loss-of-
function of C9orf72 gene product is unlikely the cause of neurodegeneration as its conditional 
elimination in mouse CNS does not induce any neurological phenotype61. It is thought that 
C9orf72-HRE cause neurodegeneration through a gain-of-function mechanism involving several 
components. Firstly, C9orf72-HRE are able to initiate repeat-associated non-ATG translation 
occurring in all 3 possible reading frames from both sense and antisense strands resulting in 
expression of several DPR species including poly-GA, poly-GR, poly-GP, poly-PR, and poly-
PA62,63, which have been reported to exert toxic effects on cells through a variety of mechanisms64. 
Secondly, G4C2 repeats can form a stable quadruplex and bind numerous RBPs causing their loss-
of-function and subsequent dysregulation of RNA metabolism. These mechanisms are not 
mutually exclusive; some poly-PR DPR were shown to be able to undergo LLPS and 





Mutations in the FUS (fused in sarcoma) gene are associated with the most aggressive, 
early-onset forms of ALS66,67 as well as rare forms of frontotemporal dementia (FTD)68,69. Like 
TDP-43 and hnRNP A1 to which it is structurally and functionally related, FUS is one of a number 
of RNA binding proteins (RBPs) that have been implicated in ALS. It is a ubiquitously expressed, 
predominantly nuclear protein that functions in DNA repair and several aspects of RNA 
metabolism, including transcription, pre-mRNA splicing, mRNA transport, stability and 
translation, as well as the processing of microRNAs and other non-coding RNAs70. 
FUS was reported to bind to thousands of transcripts and regulate their splicing71,72. Some 
studies identified its specific binding motif GUGGU72; others found an overall lack of specificity 
when binding nascent transcripts with limited preference towards GGU-containing motif73. 
However, a more in depth study of FUS binding specificity in vitro in the absence of other cellular 
components revealed a promiscuous binding to RNAs without any known motifs or secondary 
structure74 with positive Hill coefficient. These observations suggest that FUS binding preferences 
and regulated targets might be greatly affected by its binding partners and might be dependent on 
cellular context. Consistent with this hypothesis, it has been reported that FUS binds different 
targets in different cell types75. Interestingly, FUS was also found to bind conserved sequences 
within other RBPs’ transcripts and regulate their expression76. Similar cross-regulation was 
reported for a variety of RBPs77 suggesting an existence of an extensive and complicated 
regulatory network controlling RBPs. 
FUS is also known for its role in regulating transcription. It has been reported to interact 
with several transcription factors, including Spi-1/PU.1, NF-κβ, and Runx2, to initiate 
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transcription78-81 through binding directly to transcription initiation factor TFIID and RNA 
polymerase II. 
FUS is also involved in DNA damage repair. It directly interacts with HDAC1 and is 
recruited to the double-strand break sites82 in a PARP-dependent manner83. Interestingly, 
poly(ADP-ribose) has been reported to precipitate liquid-liquid phase separation of proteins with 
intrinsically disordered domains, including FUS84. This suggests a critical role of FUS in DNA 
damage repair by inducing compartmentalization of a double-strand break site85. After DNA 
damage, FUS can be phosphorylated by DNA-PK86 or ATM87 kinases supporting functional 
involvement of FUS in maintenance of genome stability. Two independently generated mouse 
lines with homozygous FUS knockout88,89 show signs of genomic instability, including increased 
DNA damage in response to mitogenic stimuli, male sterility and increased sensitivity to ionizing 
radiation. 
Although FUS is a predominantly nuclear protein, it has been reported to have specific 
functions in the cytoplasm related to mRNA transport, regulation of mRNA stability and local 
translation. FUS facilitates mRNA transport to dendrites90 and is localized to post-synaptic 
densities of dendrites91,92 where it is involved in activity-dependent translation. Interestingly, ALS-
associated FUS mutations have been reported to increase the levels of FUS protein at synapses 
resulting in disruption of synaptic mRNA stability and translation93,94. 
To date, more than 50 different FUS mutations have been identified in patients with ALS95, 
which together account for approximately 4% of familial cases and < 2% of sporadic ALS 
patients16,95. 
The functional consequences of these ALS-associated mutations on FUS are not known, 
however, while FUS loss-of-function is not sufficient to cause motor neuron degeneration in 
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vivo96, a deficiency in FUS activity may contribute to the pathogenesis of ALS. Strong evidence 
supports a toxic gain-of-function mechanism in ALS-FUS97 related to the biophysical properties 
of FUS and related, ALS-associated RNA-binding proteins that lead to liquid-liquid phase 
separation (LLPS) and the consequent formation of abnormal assemblies that underlie 
neurodegeneration in FUS-dependent ALS and related forms of FTD98. 
Most ALS-associated mutations in FUS gene occur within its C-terminal nuclear 
localization sequence (NLS) causing cytoplasmic localization of the mutant protein99. ALS-FUS 
cases are also characterized by unique neuropathology100, i.e., the presence of basophilic 
cytoplasmic inclusions in motor neurons and FUS-immunoreactive aggregates. Although most of 
the data about FUS pathology in ALS-FUS come from single case reports with different 
methodology and variable description, some studies suggest distinct clinicopathological features 
associated with different mutations101. Thus, juvenile-onset cases caused by P525L have prominent 
basophilic inclusions and round FUS-immunoreactive aggregates. Adult-onset cases, including 
cases caused by R521C mutation, featured skein-like FUS aggregates in neurons and glial cells. 
Other FUS mutations within the low complexity domain have also been reported, mostly 
in sporadic ALS. Although no autopsy reports describing FUS pathology in these cases are 
available, some of these mutations located in highly conserved regions of the protein were shown 
to alter liquid-liquid phase separation (LLPS) properties of FUS and promote irreversible 
aggregation, supporting their pathogenicity102,103. 
 
Altered mRNA metabolism as a common pathophysiological mechanism in ALS 
Both TDP-43 and FUS are RBPs involved in multiple stages of RNA regulation, including 
transcription, splicing, transport, translation, stability, storage, and degradation. Many other RBPs 
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were linked to neurodegeneration in ALS and FTD, including those closely related to FUS: EWS 
and TAF15104, hnRNP A1105, hnRNP A2B1105, and MATR3106. Multiple RBPs were also found to 
be sequestered directly or indirectly by G4C2 hexanucleotide repeat expansion in С9orf 72 gene 
forming stable quadruplexes, including hnRNP H107-109, hnRNP A1108,109, hnRNP A3109,110, 
SRSF2108, ALYREF108, FUS108, EWS108,109, TDP-43109, SF2109, SC35109, and others. 
Interestingly, many of these RNA-binding proteins contain a flexible prion-like domain45 
making them capable of undergoing LLPS. Although the prion-like domain is itself sufficient for 
LLPS, other domains of RBPs and RNA binding can regulate this process111 to form various 
membrane-less organelles under physiological conditions. Many ALS-associated mutations in 
these proteins have been shown to increase their propensity to undergo irreversible LLPS, possibly 
sequestering other proteins and RNA species. Dipeptide repeats translated from C9orf72 
hexanucleotide repeats expansion have also been shown to cause LLPS65, strengthening the link 
between LLPS-capable proteins (including prion-like domain-containing RBPs), associated 
alterations in RNA metabolism, and neurodegeneration. 
Increasing evidence supports a more widespread involvement of FUS in the pathogenesis 
of other forms of non-SOD1 ALS. For example, FUS immunoreactivity was reported to co-localize 
with ubiquitin- and TDP-43-positive aggregates in all non-SOD1 cases112. Cytoplasmic 
mislocalization of FUS was also reported in sporadic ALS cases not associated with FUS 
mutations113. Another study found an increase in detergent-insolubility of numerous RNA-binding 
proteins independently associated with ALS, including TDP-43, FUS, hnRNP A1, and others, in 
most C9orf72 and a significant proportion of sporadic cases114. This insolubility was also 
associated with a high degree of functional splicing alterations supporting RNA metabolism 
dysregulation as a common pathogenic mechanism of non-SOD1 ALS.  
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FUS mouse models 
Several mouse models of ALS have been previously reported115 most of which were 
generated using a transgenic approach. One of the earlier models in which WT FUS was 
overexpressed under a mouse prion promotor116 provided the evidence for dose-dependent FUS 
toxicity, demonstrating that just a 1.7-fold increase in total FUS in homozygous animals was 
sufficient to cause MN degeneration and accompanying ALS-like pathology. Hemizygous animals 
with 1.4-fold FUS overexpression, however, did not develop MN loss. 
Several other transgenic FUS models with highly variable phenotypes have been reported 
that used different promotors, modeled different ALS-associated mutations in FUS, and used 
different technical approaches. However, several issues complicate the interpretation of data from 
these transgenics, raising questions about the relevance of these model systems to ALS. If random 
integration is used, a variable number of copies of the transgene integrates into the mouse genome. 
Depending on the site of integration, this might result in disruption of unrelated endogenous mouse 
genes and inconsistent transgene expression. In addition, different groups used different promotors 
resulting in variable patterns and levels of FUS expression. Therefore, this approach makes it 
impossible to compare the effects of different ALS-associated FUS mutations on WT protein. 
Targeted transgene knock-in in ROSA26 or another locus could partially solve this problem. A 
previous transgenic FUS model generated in the Shneider laboratory96 had a targeted knock-in of 
human FUS cDNA (WT, R521C, and P525L) in a MAPT locus. Because different FUS protein 
species are transcribed from the same locus, this approach enables comparison between various 
FUS mutations. However, transgenes expressed from cDNA under artificial promotor from an 
unrelated locus lack any endogenous regulatory elements controlling transcription and/or 
translation of the transgenic protein. This is important for proteins such as FUS that autoregulate 
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their own expression level, a mechanism that is reportedly impaired by ALS-associated 
mutations117,118. Lastly, the presence of exogenous FUS can to an extent downregulate the 
expression of endogenous murine FUS resulting in varying degree of FUS expression and function. 
Due to the challenges of interpreting variable phenotypes reported from different 
transgenic FUS models, knock-in mice were developed that bear genetic mutations directly in the 
endogenous mouse FUS locus. This approach allows preservation of all endogenous elements and 
regulatory pathways controlling gene expression and results in physiological levels of FUS 
expression. 
The first knock-in mouse model of ALS-FUS was reported in 2016119. A cDNA sequence 
of exons 13 and 14 of FUS followed by a stop signal and flanked by loxP sites was introduced into 
intron 12 of the mouse FUS locus to generate ΔNLS mice. This construct resulted in a mature FUS 
transcript lacking exon 15, which encodes most of the NLS. Moreover, it allowed Cre-dependent 
reversal of mutant protein to WT. This study showed the necessity of mutant FUS expression in 
MN for neurodegeneration, supporting cell-autonomy of this process. It also supported the 
hypothesis of gain-of-function mechanism of mutant FUS toxicity by comparing the phenotype of 
ΔNLS/ΔNLS mice to the FUS knockout phenotype. However, ΔNLS allele also lacks 3’ UTR 
possibly impairing an important mechanism regulating FUS expression117. FUS protein promotes 
biogenesis of miR -141/200a which, in turn, bind to their specific recognition motif within the 
3’ UTR of the FUS mRNA transcript, causing its degradation. In addition, no similar pathogenic 
mutation resulting in exon 15 exclusion and translation of the truncated protein from FUS 
transcript has been reported to occur in an ALS patient. One recent clinical case report120 identified 
a splice acceptor site mutation in intron 14 of FUS resulting in exon 15 skipping in a patient with 
familial ALS. However, this transcript was not translated, reportedly due to NMD-mediated 
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degradation, resulting in overall reduction in WT FUS levels. Although the authors of this clinical 
case report concluded that this mutation caused ALS through a loss-of-function mechanism, no 
evidence of this mutation’s segregation with the disease in the family tree was provided to establish 
a causal connection. 
Another knock-in mouse model of ALS-FUS was reported in 2017121. To generate 
FUSDelta14 allele model of the human G466VfsX14 mutation, the authors introduced a splice 
acceptor site mutation into intron 13 of mouse FUS locus and humanized the part of exon 15 for 
the resulting frame-shift protein sequence to match the human mutant allele. The resulting 
truncated FUS protein mislocalized to the cytoplasm and caused late-onset MN degeneration. 
These results are similar to our data obtained from an independently generated conditional Δ14 
allele. However, our approach to generate this allele by flanking exon 14 with loxP sites has an 
additional advantage of conditional nature of mutant protein expression that could be controlled 
with Cre-mediated recombination. 
The most recent reported knock-in mouse model of ALS-FUS is the R513C model of the 
human R521C mutation122, the most common FUS mutation associated with adult-onset ALS. 
These mice develop significant MN loss at 2 years of age. Although earlier functional changes and 
behavioral abnormalities could also be detected, no detailed timeline of MN degeneration and 
associated processes including selective denervation and gliosis was provided. 
 
ALS therapeutics 
Despite significant progress in understanding etiology and mechanisms of ALS, no 
effective treatment has been developed. Most therapeutic interventions for ALS aim to treat arising 
symptoms such as spasticity, muscle cramps, sialorrhea, pain, dysphagia, dysarthria, and 
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respiratory insufficiency. Currently, only two therapeutics are FDA-approved for the treatment of 
ALS, however, the clinical benefit they provide is modest. 
Riluzole 
Riluzole is a tetrodotoxin-sensitive sodium channel blocker123 that is considered to exert 
its neuroprotective effects by decreasing glutamatergic neurotransmission in CNS. Although it was 
shown to inhibit kainite and NMDA receptors124 in vitro and induce the same physiological effects 
of competitive NMDA antagonists in vivo, no direct binding of riluzole to any glutamate receptors 
was observed125. Riluzole’s effects on glutamatergic neurotransmission are thought to be indirect, 
through inhibition of glutamate release126 or increased uptake of glutamate at synapses127. 
Riluzole was approved by FDA in 1995 after a randomized clinical trial of 155 patients 
showing an improved overall survival at 12-months follow-up128. However, this effect was much 
greater in patients with bulbar-onset disease and the observed survival benefit in patients with 
limb-onset disease in this study was not statistically significant. A larger follow-up study involving 
959 patients showed a modest increase in tracheostomy-free survival with no significant difference 
in functional tests or mortality129. Both these studies only included younger, newly diagnosed ALS 
patients; a subsequent study of riluzole in patients with advanced disease and/or patients over 75 
years old showed no significant effect on the study outcomes130. 
Currently, riluzole is recommended first-line treatment that should be started shortly after 
ALS diagnosis. Based on the aforementioned trials, if started early, it is estimated to extend the 
survival of ALS patients for 2-3 months. However, real-world evidence studies conducted in the 
past years show a more profound clinical benefit of extended survival ranging from 6 to 21 
months131. However, these results are obtained based on retrospective studies and are not free from 
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selection bias and confounding since the same factors contributing to whether a patient takes 
riluzole (e.g., lack of access to medical care) could also affect survival. 
Edaravone 
Edaravone is considered to be an antioxidant and free radical scavenger with a plethora of 
biological effects132 and unknown mechanism(s) of action. It is used as a neuroprotective agent for 
acute ischemic stroke within 24 h of onset in Japan133 and was subsequently repurposed for the 
treatment of ALS. 
Edaravone received an FDA approval in 2017 based on a repeated phase 3 clinical trial134 
showing a modest decrease in ALSFRS-R (revised ALS Functional Rating Scale) decline in treated 
group in comparison to a placebo group in patients with very early ALS stage. The study only 
enrolled patients within 2 years of the symptoms onset who scored at least 2 (out of 4) in each of 
the 12 components of ALSFRS-R and had forced vital capacity of at least 80% of predicted at 
baseline. These criteria were based on a post-hoc analysis of a previously failed phase 3 trial of 
edaravone135 that did not show a statistically significant improvement of the rate of ALSFRS-R 
decline.  
Several post-marketing retrospective and observational studies of edaravone in unselected 
groups of patients revealed no clinical benefit of the treatment136,137 suggesting that further 
clarification is needed regarding the selection criteria for patients who would likely benefit from a 
treatment. One study of long-term edaravone administration in Japan138 showed a modest 
improvement ALSFRS-R decline rate and survival in the treated group, however, the control group 
had an overrepresentation of patients with bulbar-onset ALS (33% vs 11% in edaravone-treated 




Edaravone is administered intravenously over 1-hour infusion daily on a “2 weeks on, 2 
weeks off” schedule, which might be challenging to many patients. An orally available form of 
edaravone is currently in clinical trial (NCT04165824). 
 
Summary of the thesis 
To develop a faithful model of ALS-FUS to explore disease mechanisms, identify 
therapeutic targets and test therapeutic candidates, we generated a series of FUS knock-in mouse 
lines in which ALS-causing mutations were targeted directly to the endogenous mouse FUS locus. 
We provide genetic evidence that despite a partial loss-of-function associated with the equivalent 
of the human FUS P525L mutation (mouse FUS P517L), and a truncation mutation (G466VfsX14 
or Δ14) associated with rapidly progressive, juvenile-onset ALS139, expression of these mutant 
forms of FUS in vivo at physiological levels leads to progressive, age-dependent motor neuron 
(MN) degeneration that is dose-dependent, and selective for MN subpopulations known to be 
preferentially vulnerable in ALS patients and related mouse models of familial ALS. Using a 
conditional allele of Δ14, we demonstrate that FUS-dependent motor neuron degeneration is a cell 
autonomous process, driving secondary inflammatory changes that do not depend on mutant FUS 
expression in the reactive cells but may contribute to neurodegeneration. In these knock-in mouse 
models of ALS-FUS, toxicity correlates with the degree of insolubility of FUS and other RBPs, 
which is associated with functional deficiency of these related, phase-separating proteins. 
We demonstrate that an experimental anti-sense oligonucleotide (ASO) that targets the 
FUS transcript (ION363) effectively silences wild type and mutant FUS in the brain and spinal 
cord of the P517L and Δ14 heterozygous mice. Consistent with our model of a dose-dependent, 
gain-of-function mechanism of disease, we show that a single intracerebroventricular (ICV) 
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injection of this FUS ASO delays the onset of motor neuron degeneration in a compound 
heterozygous mutant FUS mouse with an accelerated, ALS-like phenotype. In a first-in-human 
study, we find that repeated, intrathecal administration of ION363 in an ALS-FUS patient with a 
FUSP525L mutation results in the dramatic suppression of FUS expression in the brain and spinal 
cord, and the reduction of the FUS aggregates that are the pathological hallmark of this disease. 
We provide evidence to support the clinical application of ION363 in the treatment of ALS-FUS 
and related FUS-dependent proteinopathies. 
Finally, we demonstrate how the newly generated knock-in mouse model of ALS-FUS 
could be used to evaluate the efficacy of additional proposed drug candidates, including hnRNP U 
or UPF1 gene therapy.  
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 : Phenotypic characterization of FUS knock-in mice 
To study the effects of ALS-causing mutations on normal FUS function and to model the 
toxicity of mutant FUS faithfully in vivo, two ALS-FUS mutations associated with a rapidly 
progressive, juvenile-onset form of ALS were introduced into the mouse FUS locus as a part of 
the previous work in the laboratory140. The mouse FUS P517L mutation (Fig. 1-1A) is equivalent 
to the human FUS P525L allele141. The mouse FUS Δ14 mutation (Fig. 1-1B) is equivalent to the 
human G466VfsX14 C-terminal FUS truncation mutation139, which causes skipping of FUS exon 
14. To enable conditional expression of the FUS Δ14 mutant, we generated the wild type FUS-
expressing c14 allele, which can be converted to the truncated mutant FUS-producing Δ14 allele 
via Cre-mediated recombination (Fig. 1-1B). 
 
Mouse FUS alleles carrying ALS-associated mutations express endogenous levels of 
FUS protein 
Previous expression analysis of the FUS mRNA transcripts from these mice revealed 
comparable levels between WT and both mutant alleles. Western analysis of FUS protein in the 
P517L/WT and P517L/ P517L animals showed a single band similar in size and intensity to that 
of a WT/WT animal (Fig. 1-1C), and as expected, two FUS bands in the Δ14/WT and compound 
heterozygous P517L/ Δ14 mutants - the top band corresponding to the full-length wild type or 
P517L mutant FUS protein (518AA), respectively, and the bottom band to the truncated Δ14 FUS 
protein (471AA) (Fig. 1-1C). Taken together, these data show that we successfully introduced two 
pathogenic ALS-FUS mutations into the mouse germline, and that the mutant alleles are expressed 





A. Schematic of creation of mutant FUS knock-in alleles. Top shows the murine FUS locus and bottom shows the 
P517L targeting vector used for homologous recombination. Exons are represented as gray (5’ UTR and 3’ UTR) and 
white (coding sequence) rectangles. FRT-site downstream of the 3’ UTR, is the “scar” left after removal of Neomycin 
resistance cassette. 
B. Conditional c14 allele (top) has exon 14 flanked by LoxP sites (yellow triangles). Cre recombinase-dependent 
recombination at the LoxP sites in c14 excises exon 14 and converts it to the mutant Δ14 allele. In addition, part of 
the mouse exon 15 (red rectangle) is “humanized” - replaced with the corresponding human exon 15 sequence. This 
modification does not affect the in-frame protein sequence (c14 allele produces wild type mouse FUS protein) but 
alters the Δ14 C-terminal amino acid sequence to mirror the out-of-frame reading of human G466VfsX14 mutant 
exon 15. 
C. Representative immunoblot of brain total protein extracts from newborn animals using Proteintech anti-FUS 
antibody. 
 
FUS knock-in animals develop late-onset motor neuron degeneration 
Having reproduced the genotype of ALS-FUS patients in heterozygous P517L/WT and 
Δ14/WT mutant FUS knock-in mice, we first asked whether these mutations are sufficient to cause 
selective motor neuron degeneration in the relatively short lifespan of a mouse by examining the 
skeletal muscle and the spinal cords of adult heterozygous mutants and wild type controls.  
Denervation of fast-fatigable (FF) motor units in skeletal muscle precedes the spinal motor 
neuron loss in ALS patients and in SOD1, TDP-43, and FUS mouse models of ALS96,142,143. 
Therefore, we first looked for evidence of denervation in the tibialis anterior (TA) muscle, which 





post-synaptic skeletal muscle surfaces in neuromuscular junctions (NMJs), we found that at 1 year 
of age, approximately 5% and 8% of the TA NMJs were at least partially denervated in P517L/WT 
and Δ14/WT mutant mice, respectively, compared to 0.8% denervation observed in the wild type 
mice (Fig. 1-2B,E). By 1.5 years, TA denervation increased to 11% and 10% in P517L/WT and 
Δ14/WT mutants, respectively, and persisted at a similar level at 2 years of age (Fig. 1-2B,E). In 
contrast, the soleus muscle (Sol), innervated mostly by slow (S) MNs that are relatively spared in 
ALS patients and animal models, remained innervated in all 2-year-old animals (Fig. 1-2B,E). 
To determine if the TA denervation precedes MN degeneration in heterozygous FUS 
mutants, we used choline acetyl transferase (ChAT) as a marker to count the cholinergic MNs that 
innervate these hindlimb muscles in the lumbar spinal cord (Fig. 1-2C,D). These studies showed 
no loss of MNs at 6 months or 1 year of age, but at 1.5 years we observed approximately 11% 
fewer MNs in both the P517L/WT and Δ14/WT mutants compared to the wild type animals (Fig. 
1-2D). By 2 years of age, MN loss in both the P517L/WT and Δ14/WT mutants progressed to 
approximately 22% and remained at a similar level at 2.5 years (Fig. 1-2D). Consistent with other 
mouse ALS models144, MN loss was restricted to alpha motor neurons such that at 2 years of age, 
31% and 26% of the alpha-MNs were lost in P517L/WT and Δ14/WT mutants, respectively, while 























A. Representative images of tibialis anterior (TA) muscle innervation in 2-year-old WT/WT (left), P517L/WT 
(middle), and Δ14/WT (right) animals. Muscle innervation was determined by co-localization of markers for motor 
axon terminals (anti-synaptophysin antibody, green) and post-synaptic NMJ acetylcholine receptors (fluorophore-
conjugated α-bungarotoxin, or α-BTX, red). In addition, motor axons were labeled with anti-neurofilament antibody 
(blue). White asterisks indicate fully denervated motor endplates (prominent α-BTX with no overlapping 
synaptophysin, absent neurofilament) and white arrows indicate partially denervated NMJs (partial overlap of 















































































B. Percentage of completely innervated NMJs (i.e., not partially or completely denervated) in tibialis anterior left) and 
soleus (right) muscles of WT/WT (black), P517L/WT (red), and Δ14/WT (blue) animals. N=3 animals per group at 1 
and 2 years and 4 animals per group at 1.5 years. 
C. Representative images of lumbar level 5 (L5) spinal cord ventral horns of 2-year-old WT/WT (left), P517L/WT 
(middle), and Δ14/WT (right) animals stained with anti-ChAT antibody (white). Compass mark indicates dorsal (D), 
ventral (V), medial (M) or lateral (L) orientation. Scale bar=100µm. 
D. Numbers of ChAT positive motor neurons at lumbar levels 4 and 5 in WT/WT (black), P517L/WT (red), and 
Δ14/WT (blue) animals normalized to the wild type controls. N=3 animals per group at 1 and 2 years and 5 animals 
per group at 1.5 years. 
E. Percentages of NMJs classified as fully innervated (green), partially denervated (yellow), and fully denervated (red) 
in the tibialis anterior (left) and soleus (right) muscles in WT/WT, P517L/WT, and Δ14/WT animals. *P<0.05, 
**P<0.01 and ***P<0.001 indicates significant differences in fully denervated NMJs between the corresponding 
genotype and WT controls using two-way ANOVA with Dunnett’s post hoc test. Error bars represent SD. N=3 animals 
per group at 1 and 2 years and 4 animals per group at 1.5 years. 
F. Histogram of MN soma cross-sectional areas of WT/WT (black), P517L/WT (red), and Δ14/WT (blue) animals. 
MNs with soma area ≥475 µm2 were classified as α- and < 475 µm2 as γ-MNs. Inset shows the numbers of ChAT-
positive γ-MNs (left) or αMNs (right) at lumbar levels 4 and 5 in 2-year-old WT/WT (black), P517L/WT (red), and 
Δ14/WT (blue) animals normalized to the wild type controls. *P<0.05, **P<0.01 and ***P<0.001 using one-way 
ANOVA with Tukey’s post hoc test. Error bars represent SD. N=3 animals per group. 
For B and D: *P<0.05, **P<0.01 and ***P<0.001, using two-way ANOVA with Tukey’s post hoc test. Error bars 
represent SD. 
 
Further, as gliosis has been associated with ALS pathology in patients and mouse 
models96,145,146, we analyzed the expression and spatial distribution of Iba1 and GFAP to monitor 
the proliferation of microglia and astrocytes, respectively. Significant elevations in Iba1 and GFAP 
were observed in the spinal ventral horns of both heterozygous mutant animals compared to wild 
type controls starting at 1 year of age (Fig. 1-3B,D). Thus, both gliosis and NMJ denervation 

















A,C. Representative images of lumbar level 5 (L5) spinal cord ventral horns of 1.5-year-old WT/WT (left), P517L/WT 
(middle), and Δ14/WT (right) animals stained with anti-Iba1 antibody (A) or anti-GFAP antibody (C). 
B. Density of Iba1-positive microglial cells at lumbar levels 4 and 5 in WT/WT (black), P517L/WT (red), and Δ14/WT 
(blue) animals. N=3 animals per group. 
D. Percentage of cross-sectional area that is GFAP-positive at lumbar levels 4 and 5 in WT/WT (black), P517L/WT 
(red), and Δ14/WT (blue) animals. 
For B and D: *P<0.05, **P<0.01 and ***P<0.001, using two-way ANOVA with Tukey’s post hoc test. Error bars 
represent SD. N=3 animals of each genotype for each group. 
 
Our studies of heterozygous ALS mutant FUS knock-in mice show that a single copy of 
P517L or Δ14 mutant allele is sufficient to cause gliosis and NMJ denervation, followed by 
selective MN degeneration involving the same MN subtypes that are preferentially vulnerable in 
ALS-FUS. This pathology is not restricted to the lumbar spinal cord, as similar trends in 
denervation, MN degeneration, and gliosis were observed in the diaphragm muscle and cervical 








































































A. Percentage of completely innervated NMJs (i.e., not partially or completely denervated) in the diaphragm muscles 
WT/WT (black), P517L/WT (red), and Δ14/WT (blue) animals. 
B,C. Numbers of Iba1-positive microglial cells (B) or GFAP-positive astroglial cells (C) within phrenic nucleus at 
cervical levels 3 through 5 in WT/WT (black), P517L/WT (red), and Δ14/WT (blue) animals. 
D-F. Numbers of ChAT positive α- (E), γ- (F), or all (D)motor neurons in phrenic nucleus at cervical levels 3 through 
5 in WT/WT (black), P517L/WT (red), and Δ14/WT (blue) animals normalized to the wild type controls. 
*P<0.05, **P<0.01 and ***P<0.001, using two-way ANOVA with Tukey’s post hoc test. Error bars represent SD. 














































































































Cytoplasmic mislocalization of mutant FUS 
To create an accurate model of ALS-FUS, we avoided the use of engineered epitope tags 
that can have unpredictable effects on mutant FUS expression, subcellular localization, and 
function. Therefore, to distinguish mutant from wild type protein in the mutant FUS knock-in mice, 
we generated antibodies specific to P517L and Δ14 mutant FUS proteins. Mutant specificity of 
these novel antibodies was confirmed by the absence of staining in WT/WT spinal cord sections 
(Fig. 1-5A,B). Unexpectedly, several commercial polyclonal FUS antibodies raised to distinct, 
non-overlapping epitopes failed to show reactivity with either P517L or Δ14 mutant FUS proteins 
in fixed tissues. Using these wild type and mutant-specific antibodies, we observed diffuse, 
cytoplasmic mislocalization of mutant but not wild type FUS in P517L/WT and Δ14/WT animals, 
as well as strong nuclear staining for mutant FUS (Fig. 1-5A,B). Differences in immunoreactivities 
of mutant and wild type FUS were also observed on western blot analysis of neonatal brain tissues 
in denaturing conditions, wherein five commercially available anti-FUS antibodies demonstrated 
a range of affinities for mutant FUS relative to wild type (Fig 1-5C). Differential antibody 
reactivity on WB under denaturing conditions could not be explained solely by conformational 
changes of the mutant protein and suggests different post-translational modifications between WT 
and mutant FUS. Interestingly, two commercial antibodies showing the most markedly reduced 
affinity towards mutant FUS are raised against the same epitope – the most extreme N-terminal 
amino acids (1-50). This region was previously reported to have numerous phosphorylation sites 
by various kinases including DNA-PK; moreover, phosphorylation of these sites decreases LLPS 
properties of FUS protein147. 
We next quantified the cytoplasmic vs. nuclear distribution of wild type and mutant FUS 
by subcellular fractionation and western blot analysis (Fig. 1-5D). Similar to immunostaining 
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experiments, we found that a minority (~26-45%) of wild type FUS is cytoplasmic in the spinal 
cords of 1 year old wild type, P517L/WT, and Δ14/WT animals (Fig. 1-5E). In contrast, the 
majority of mutant FUS (~68-86%) is cytoplasmic in P517L/WT and Δ14/WT mutants (Fig. 1-
5E). While mutant FUS does not appear to carry wild type FUS into the cytoplasm, we asked if 
any of the RNA-binding proteins (RBPs) known to interact directly or indirectly with FUS148,149 
were also mislocalized. Indeed, a number of these RBPs (including TDP-43, hnRNP H, hnRNP U 
in P517L/WT; hnRNP U in Δ14/WT) are observed at a significantly higher proportion in the 
cytoplasm of mutant animals compared to wild type controls (Fig. 1-5E). Taken together, these 
experiments demonstrate that mutant, but not wild type FUS is selectively mislocalized to the 




















A,B. Immunostaining of adult spinal cord sections of 1-year-old heterozygous mutant (P517L/WT and Δ14/WT) and 
WT/WT mice using Abcam ab84078 anti-FUS (FUS, white) and P517L or Δ14 (red) antibodies. Note the cytoplasmic 
staining with P517L and Δ14 antibodies in the animals that express the corresponding mutant FUS protein (upper 
panels) and the absence of staining of wild type FUS protein in WT/WT animals using either the P517L or the Δ14 
antibodies (bottom panels). Scale bar: 20µm. 
C. Denaturing immunoblot of brains of newborn mice of the indicated genotypes demonstrates variable affinities of 
five commercially available anti-FUS antibodies for mutant relative to wild type FUS. Note, for example, absence of 
visible bands for either P517L or Δ14 mutant FUS protein with the FUS-Abcam[1-50] antibody. In addition, absence 
of visible bands for WT protein confirms the specificity of P517L and Δ14 antibodies for mutant FUS. 
D,E. Western blot and quantification of nucleo-cytoplasmic fractionation of brain tissue of 1-year-old wild type 
(WT/WT) and heterozygous mutant (P517L/WT and Δ14/WT) animals. *P<0.05, **P<0.01 and ***P<0.001 using 
one-way ANOVA with Tukey’s post hoc test. N=3 for all genotypes. 
*P<0.05, **P<0.01 and ***P<0.001, using two-way ANOVA with Tukey’s post hoc test. Error bars represent SD. 

























Immunostaining of human iPSC-derived MNs carrying corresponding Δ14 or P525L mutation with anti-FUS 
antibodies (Bethyl A300-293A); other commercial antibodies provide similar staining pattern. 
 
Interestingly, immunostaining of human iMNs carrying the corresponding mutations (Fig. 
1-6) with commercial anti-FUS antibodies revealed exclusively nuclear staining in WT cells and 
diffuse cytoplasmic staining in both mutant lines, more prominent in Δ14/WT cells in comparison 
to P525L/WT ones. Analysis of the same commercial antibodies showing differential affinity to 
WT versus mutant protein in mouse tissues did not reveal a similar pattern in human motor neurons 
differentiated from iPSCs – all tested antibodies readily stained cytoplasm in mutant but not WT 
cells. Although it might reflect differences between human and mouse protein post-translational 
modifications, it could also be an in vitro only phenotype resulting from differentiating and 
maintaining MNs under artificial culturing conditions. The latter is supported by the observation 
that ES-derived MNs from the P517L knock-in mouse line show cytoplasmic signal when stained 




Simultaneous loss- and gain- of function of mutant FUS 
In previous studies96, we demonstrated that postnatal FUS deficiency is insufficient to cause MN 
degeneration, and concluded based on indirect evidence that the toxicity of mutant FUS was a 
consequence of a gain-of-function. However, as gain- and loss-of-function mechanisms are not 
exclusive, these studies left open the question of whether partial loss-of-function caused by ALS-
associated FUS mutations may contribute to the pathogenesis of ALS-FUS. Here, using the P517L 
and Δ14 mutant FUS knock-in alleles in combination with the wild type and knockout (KO) FUS 
alleles, we took a genetic approach to assess the relative contribution of gain and loss of function 
mechanisms to the degenerative MN phenotype we observed in vivo in these knock-in animals. In 
a series of experiments, we crossed mice carrying FUS wild type (WT), mutant knock-in (P517L 
or Δ14), and KO alleles to generate homozygous, heterozygous, and hemizygous animals for each 
FUS allele. In the previous studies in our laboratory140, a similar functional rescue of the knockout 
phenotype by mutant FUS alleles was conducted, however, the KO allele used for those 
experiments88 resulted in a low level expression of a truncated FUS protein with some potentially 
retained functionality. Therefore, we decided to replicate this study using a different KO allele that 
does not express any FUS protein at all. 
Evidence for partial function of mutant FUS 
FUS plays a critical role in development, as demonstrated by the perinatal lethality of the 
elimination of FUS in knockout mice (KO/KO)88. To test the functional effect of the P517L and 
Δ14 mutations on FUS, we first asked whether either the P517L or Δ14 mutant alleles could rescue 
the knockout phenotype. Lacking all FUS function, KO/KO mice were born abnormally small, 
with a body weight approximately 74% of matched wild type controls, and all died within several 
hours of birth (Fig. 1-7A,B). Expression of one copy of the wild type allele is sufficient to 
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completely rescue the FUS knockout phenotype such that WT/KO animals are indistinguishable 
from matched wild type controls in birth weight and survival (Fig. 1-7A,B). In contrast, 
hemizygous mutants expressing only a single copy of P517L or Δ14 FUS, although born either 
similar in size (Δ14/KO) or slightly larger (P517L/KO) than KO/KO animals, were only able to 
survive for several days (Δ14/KO) to several weeks (P517L/KO) (Fig. 1-7A,B). These experiments 
demonstrate that P517L and Δ14 mutant proteins retain partial FUS function, and incompletely 
rescue the FUS knockout phenotype.  
Evidence for gain of function of mutant FUS 
The partial loss-of-function caused by the P517L and Δ14 mutations could selectively affect 
specific activities of FUS, or incompletely reduce all protein activities. In the latter case, two copies 
of the mutant allele would be expected to restore more of the normal FUS activity and further 
improve the knockout phenotype. Indeed, this is the case for Δ14, as the homozygous mutants 
(Δ14/ Δ14) demonstrated an improved survival compared to the hemizygous mutants (Δ14/KO) 
despite similar birth weights (Fig. 1-7A,B). In contrast, P517L/P517L animals were born at lower-
than-expected Mendelian ratios, were smaller than P517L/KO animals, and none survived more 
than several hours after birth (Fig. 1-7A,B). Surprisingly, P517L/Δ14 animals also had reduced 
survival compared to the P517L/KO animals (Fig. 1-7A,B). The exacerbation of the low birth 
weight and poor survival phenotype of the P517L/KO mutants by additional P517L protein (in 
P517L/P517L homozygous animals) or Δ14 protein (in P517L/Δ14 compound heterozygous 
mutants) demonstrates dose-dependent gain-of-function toxicity of P517L and Δ14 mutant FUS. 
The increased severity of the P517L/P517L compared to the P517L/Δ14 phenotype suggests that 
P517L is more toxic than Δ14 mutant FUS, and this conclusion is further supported by decreased 



















A. Birth weight of mice with the indicated combinations of FUS WT, P517L, Δ14, and null-knockout (KO) alleles. 
*P<0.05, **P<0.01 and ***P<0.001, using one-way ANOVA with Tukey’s post hoc test. Dashed lines represent 
median and terciles. N=13-183 animals per genotype. 
B. Kaplan-Meier survival curves for mice with the indicated combinations of FUS WT, P517L, Δ14, and null-
knockout (KO) alleles. 
C. Kaplan-Meier survival curves for successfully weaned WT/WT, P517L/WT, Δ14/WT, and WT/KO mice. Both 
heterozygous mutants but not WT/KO have significantly decreased median survival age compared to wild type 
controls. All possible pairwise comparisons were performed using Log-rank (Mantel-Cox) test and the resulting p-






























































































Detergent insolubility of FUS and multiple RNA-binding proteins  
Mutant FUS toxicity may relate to its irreversible incorporation into cytoplasmic inclusions or 
detergent-insoluble protein aggregates, resulting in aberrant RNA processing151,152. While we do 
not observe obvious cytoplasmic FUS inclusions in MNs by immunofluorescent staining, 
biochemical fractionation of brains of P0 animals reveals increased partitioning of FUS from the 
soluble to the sarkosyl-insoluble fractions in P517L/WT and P517L/P517L animals compared to 
wild type controls. Indeed, side-by-side analysis of only the detergent-insoluble fractions from 
individual brains fractionated in the same experiments clearly shows the increase in detergent-
insoluble FUS in P517L/WT relative to wild type animals, and a further accumulation of insoluble 
FUS in P517L/P517L relative to P517L/WT animals (Fig. 1-8A,B). Given the insolubility of a 
broad range of related RBPs that we observed in the brain and spinal cord of ALS/FTD patients 
carrying the C9orf72 expansion mutation, and in sporadic ALS114, we looked in the P517L/WT 
and P517L/P517L animals to see if FUS insolubility was associated with a similar increase in 
insoluble RBPs. We found increased partitioning of TDP-43 as well as hnRNP A1, hnRNP H, 
hnRNP U and other RBPs from the soluble to the detergent-soluble and detergent-insoluble 
fractions in newborn (Fig. 1-8A,B) and 2-year-old P517L/WT animals (Fig. 1-8C,D). To validate 
that the RBP insolubility in the FUS mutant mice reflects pathological changes in ALS-FUS, we 
performed the same fractionation on a postmortem brain sample from an ALS-FUSP525L patient 
and demonstrated insolubility of both wild type and P525L mutant FUS that was not seen in the 
age-matched, non-neurological control brain (Fig. 1-8E,F). Moreover, as in the FUS mice, we also 
observed increased partitioning of TDP-43, hnRNP A1, hnRNP H, hnRNP U and other RBPs from 
the soluble to the detergent-soluble and detergent-insoluble fractions of the FUSP525L ALS brain, 
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demonstrating that in ALS-FUS patients, as in the mutant mice, FUS drives the insolubility of 
related RBPs, including TDP-43 (Fig. 1-8E,F). 
To test the functional significance of this increased insolubility of FUS and other RBPs, we looked 
in the mutant animals for evidence of aberrant splicing of their target pre-mRNAs, similar to that 
which we described previously in brain and spinal cord tissue from C9orf72-positive and gene-
negative ALS/FTD patients114. As in those cases, RBP insolubility in the Δ14/WT and P517L/WT 
animals was also associated with alteration in splicing. For example, analysis of two targets of 
hnRNP H demonstrated decreased inclusion of ATXN2 exon 24 and increased inclusion of 
hnRNPDL exon 8 – consistent with decreased hnRNP H activity – in Δ14/WT and P517L/WT 
animals compared to wild type controls (Fig. 1-8G). P517L/WT demonstrated a greater magnitude 
of detergent insolubility and splicing alterations compared to Δ14/WT animals (Fig. 1-8D,G), once 
again suggesting increased toxicity of P517L over Δ14. 
Taken together, these experiments reveal that normal FUS function is essential for perinatal mouse 
survival, and that P517L and to a lesser extent Δ14 mutant FUS protein retains sufficient activity 
for a single copy of either allele to rescue the knockout phenotype, albeit partially. However, when 
expressed at higher levels in homozygous or compound heterozygous animals, mutant FUS protein 
is toxic in a dose-dependent manner, decreasing mutant survival. This toxicity is associated with 
increased insolubility of FUS, TDP-43 and related RBPs, many of which have been independently 
implicated in the pathogenesis of ALS. This insolubility leads to the consequent loss-of-function 



























A,C. Immunoblot of sarkosyl insoluble fractions from brains of newborn (A) or 2-year-old (C) FUS WT/WT, 




























B,D. Quantitation of protein in sarkosyl insoluble fractions from newborn (B) or 2-year-old animals (D), expressed as 
log-ratio of wild type. *P<0.05, **P<0.01 and ***P<0.001 using one-way ANOVA with Tukey´s post hoc test. N=3 
animals per genotype. 
E. Immunoblot of sarkosyl solubility fractionation of human brain stems of a non-ALS control and an ALS-FUS 
P525L patient. Sol = soluble (in hypotonic buffer), SS = sarkosyl soluble (in 1% sarkosyl and high salt), and SI = 
sarkosyl insoluble fractions. 
F. Immunoblot of sarkosyl insoluble fractions from human brain stem samples from a non-ALS control and an ALS-
FUS P525L patient. 
G. Relative abundance of inclusion isoforms of exons regulated by hnRNP H. The observed pattern is consistent with 
functional deficiency of hnRNP H, which promotes inclusion of exon 24 of ATXN2 (left) and inhibits the inclusion 
of exon 8 of hnRNPDL transcript (right). *P<0.05, **P<0.01 and ***P<0.001 using one-way ANOVA with Tukey’s 
post hoc test. N=4 animals per genotype. 
 
Conditional expression of FUS Δ14 protein accelerates selective motor neuron 
degeneration by a dose-dependent, cell autonomous mechanism 
Consistent with their highly pathogenic nature in ALS-FUS patients, a single copy of the 
P517L or Δ14 allele is sufficient to cause progressive motor neuron degeneration in the lifetime 
of heterozygous animals, providing a faithful mouse model of disease. As we demonstrated, 
increasing the dose of mutant FUS in the P517L/P517L, P517L/Δ14, and Δ14/Δ14 mice results in 
increased toxicity, leading to perinatal lethality, seemingly due to widespread toxicity of mutant 
FUS in embryonic development. To avoid this developmental toxicity and restrict the dose-
dependent effects of mutant FUS to MNs, we generated a Δ14/c14 mutant that carries the Δ14 
allele and the conditional FUS c14 allele - which encodes wild type FUS but is transformed into 
the Δ14 allele following Cre-dependent recombination. We used the ChAT-Cre allele153 to activate 
FUS c14 selectively in cholinergic cells so that only MNs are Δ14/Δ14 homozygous in this animal, 
while non-cholinergic cells remain Δ14/c14 and express only a single copy of the Δ14 mutant 
allele. To account for potential non-MN autonomous mutant FUS-dependent effects we generated 
additional genotypes that are MN-hetero- or homozygous in a WT or Δ14/WT background.  
To test whether a MN-restricted “double dose” of mutant FUS accelerates ALS-related 
pathology, we compared mice expressing either one or two copies of mutant FUS in MNs at 1 year 
35 
 
of age – a time point at which MN loss is not yet detected in heterozygous mutant FUS animals 
(Fig. 1-2D). As expected, no MN loss was observed at 1 year in “MN-Δ14/WT” mice expressing 
one copy of a Δ14 allele in MNs (Δ14/WT and c14/WT; ChAT-Cre) (Fig. 1-9A). In contrast, “MN-
Δ14/Δ14” mice expressing two Δ14 alleles in MNs (Δ14/Δ14, Δ14/c14; ChAT-Cre, and c14/c14; 
ChAT-Cre) all demonstrated a similar level of approximately 10% MN loss, indicating 
acceleration of MN degeneration by the expression of the second Δ14 allele in MNs (Fig. 1-9A). 
Similarly, an increase in the Iba1 microglial marker staining was observed in MN-Δ14/Δ14 
animals relative to MN-Δ14/WT mice, demonstrating that expression of the second Δ14 allele in 
MNs accelerates microgliosis (Fig. 1-9B). Time-course analysis revealed that microgliosis is first 
detected at 6 months and MN degeneration is first detected at 1 year in MN-Δ14/Δ14 mice – 
demonstrating that expression of an additional Δ14 allele in MNs of MN-Δ14/Δ14 mice accelerates 
the onset of both microgliosis and MN loss by 6 months compared to MN-Δ14/WT animals (Fig. 
1-9C-F).  
The conditional expression of Δ14 mutant FUS in MNs showed that the dosage of mutant 
protein determines the age of onset of MN degeneration in vivo. These experiments also revealed 
the cell autonomous nature of this dose-dependent toxicity. The timing of microgliosis and 
subsequent MN loss in Δ14/WT animals was identical to that c14/WT; ChAT-Cre mutants. The 
same was true in Δ14/Δ14, Δ14/c14; ChAT-Cre and c14/c14; ChAT-Cre mice, indicating that the 
MN degenerative phenotype is determined by the level of mutant Δ14 FUS expression specifically 
in MNs, without measurable contribution of mutant FUS expression in other cell types. Further, 
these data suggest that microgliosis – and other possible, cell non-autonomous contributors to MN 
degeneration – is a pathological response to mutant FUS-dependent MN pathology, as it occurs 
























A. Numbers of ChAT positive motor neurons at lumbar levels 4 and 5 in WT/WT (left), MN-Δ14/WT (center - 
c14/WT; ChAT-Cre and Δ14/WT), and MN-Δ14/Δ14 (right - c14/c14; ChAT-Cre, Δ14/c14; ChAT-Cre, and Δ14/Δ14) 
animals normalized to the wild type controls. Each of the MN-Δ14/Δ14 genotypes shows fewer lumbar MNs in 
comparison to either of MN- Δ14/WT genotypes or WT/WT group using one-way ANOVA followed by Fisher’s 




































































B. Density of Iba1-positive microglial cells at lumbar levels 4 and 5 in WT/WT (left, black), MN-Δ14/WT (center - 
c14/WT; ChAT-Cre and Δ14/WT), and MN-Δ14/Δ14 (right - c14/c14; ChAT-Cre, Δ14/c14; ChAT-Cre, and Δ14/Δ14) 
animals. Each of the MN- Δ14/WT genotypes show an increase in microglial density in comparison to WT/WT 
animals. Each of the MN-Δ14/Δ14 genotypes has increased microglial density in comparison to either of MN- 
Δ14/WT genotypes or WT/WT group. Statistical significance was determined by one-way ANOVA with Tukey’s post 
hoc test. N=3 animals per genotype. 
C. Numbers of ChAT positive motor neurons at lumbar levels 4 and 5 in WT/WT (black) and MN-Δ14/WT (c14/WT; 
ChAT-Cre and Δ14/WT, purple and blue respectively) animals normalized to the wild type controls. 
D. Density of Iba1-positive microglial cells at lumbar levels 4 and 5 in WT/WT (black) and MN-Δ14/WT (c14/WT; 
ChAT-Cre and Δ14/WT, purple and blue respectively) animals. 
E. Numbers of ChAT positive motor neurons at lumbar levels 4 and 5 in WT/WT (black) and MN-Δ14/Δ14 (c14/c14; 
ChAT-Cre, Δ14/c14; ChAT-Cre, and Δ14/Δ14, red, green, and brown respectively) animals normalized to the 
controls. 
F. Density of Iba1-positive microglial cells at lumbar levels 4 and 5 in WT/WT (black) and MN-Δ14/Δ14 (c14/c14; 
ChAT-Cre, Δ14/c14; ChAT-Cre, and Δ14/Δ14, red, green, and brown respectively) animals. 
*P<0.05, **P<0.01 and ***P<0.001 using two-way ANOVA with Tukey´s post hoc test. Error bars represent SD. 
N=3 animals per genotype. 
 
Conditional compound heterozygous model  
Since our previous experiments suggested that mutant P517L is more pathogenic than Δ14, 
we suspected that co-expression of these two mutant alleles in motor neurons would further 
accelerate disease. We therefore generated P517L/c14; ChAT-Cre (“MN-P517L/Δ14”) 
conditional compound heterozygote mutants that express both P517L and Δ14 mutant FUS only 
in MNs, on an otherwise P517L- and WT-expressing background. Immunofluorescent staining of 
spinal cords confirmed that in MN-P517L/Δ14 mice MNs express P517L and Δ14 (but not WT) 






Immunostaining of lumbar spinal cord sections of adult MN-P517L/Δ14 (P517L/c14; ChAT-Cre) animals 
using anti-ChAT (green), anti-FUS-WT (Abcam[1-50], yellow), anti-Δ14 (cyan), and mouse monoclonal anti-FUS-
P517L (red) antibodies. Note anti-FUS-P517L staining in all cells, anti-FUS-Δ14 staining only in ChAT+ cells, and 
anti-FUS-WT staining only in ChAT-negative cells. Scale bar= 100 µm. 
 
As predicted, addition of the more pathogenic P517L allele led to NMJ denervation, micro- 
and astro-gliosis at 3 months of age, and MN degeneration at 4 months in MN-P517L/Δ14 mice 
(Fig. 1-11A-D) – earlier than the corresponding changes in MN-Δ14/Δ14 animals (Fig. 1-9C-F). 
Despite this earlier onset, MN loss in MN-P517L/Δ14 mutants was limited to the same, 
selectively vulnerable pools as in the heterozygous P517L/WT and Δ14/WT mice; the vulnerable 
TA muscle demonstrated NMJ denervation, while the soleus muscle remained unaffected (Fig. 1-
11D,F). Here again, MN loss was limited to the large diameter (alpha) MNs (Fig. 1-11G) and 
ultimately plateaued at around 20% (Fig. 1-10A) - approximately the same level as in heterozygous 
P517L/WT and Δ14/WT mice (Fig. 1-2D), suggesting depletion of the same subset of vulnerable 
MNs. Of note, denervation of the TA recovered in time: re-innervation of NMJs (Fig. 1-11D), 
along with functional recovery from mild deficiencies in grip strength (Fig. 1-11E), occurred by 1 
year of age. 
39 
 
Overall, these data demonstrate cell-autonomous toxicity of mutant FUS – as conditional 
expression of the Δ14 allele selectively in MNs is sufficient for MN degeneration and gliosis. This 
toxicity is dose-dependent – expression of two mutant FUS alleles in MNs accelerates the onset of 
NMJ denervation, MN loss, and gliosis, with MN-P517L/Δ14 mice demonstrating a particularly 
early disease onset. The selective degeneration of the same subpopulation of ALS-vulnerable MNs 
in MN-P517L/Δ14 mutants as in P517L/WT and Δ14/WT animals support the conclusion that 



























A. Motor neuron numbers at lumbar level 4 and 5 of CTRL (FUS WT-expressing control, black) and MN-P517L/Δ14 
























































































































































































































































B,C. Density of Iba1-positive microglial cells (B) and percentage of cross-sectional area that is GFAP-positive (C) at 
lumbar levels 4 and 5 in CTRL (FUS WT-expressing control, black) and MN-P517L/Δ14 (FUS P517L/c14; ChAT-
Cre, green) animals. 
D. Percentage of completely innervated NMJs (i.e., not partially or completely denervated) in tibialis anterior (left) 
and soleus (right) muscles of CTRL (FUS WT-expressing control, black) and MN-P517L/Δ14 (P517L/c14; ChAT-
Cre, green) animals. 
E. Normalized grip strength of forelimbs (left) and hindlimbs (right) in CTRL (FUS WT-expressing control, black) 
and MN-P517L/Δ14 (P517L/c14; ChAT-Cre, green) animals normalized to the controls. *P<0.05, **P<0.01 and 
***P<0.001 using two-way ANOVA with Sidak´s post hoc test. Error bars represent SD. N=5-28 per group at different 
time points. 
F. Percentages of NMJs classified as fully innervated (green), partially denervated (yellow), and fully denervated (red) 
in the tibialis anterior (left) and soleus (right) muscles in CTRL (FUS WT-expressing control) and MN-P517L/Δ14 
(FUS P517L/c14; ChAT-Cre) animals. *P<0.05, **P<0.01 and ***P<0.001 indicates significant differences in fully 
denervated NMJs using two-way ANOVA with Sidak´s post hoc test. Error bars represent SD. N=3 animals per group. 
G. Histogram of MN soma cross-sectional areas of CTRL (FUS WT-expressing control, black) and MN-P517L/Δ14 
(P517L/c14; ChAT-Cre, green) animals. MNs with soma area ≥475 µm2 were classified as α- and < 475 µm2 as γ-
MNs. Inset shows the numbers of ChAT positive γ-MNs (left) or αMNs (right) at lumbar levels 4 and 5 in 2-year-old 
CTRL (FUS WT-expressing control, black) and MN-P517L/Δ14 (P517L/c14; ChAT-Cre, green) animals normalized 
to the controls. *P<0.05, **P<0.01 and ***P<0.001 using Welch’s t-test. Error bars represent SD. N=3 animals per 
group. 
For A-D, *P<0.05, **P<0.01 and ***P<0.001 using two-way ANOVA with Sidak´s post hoc test. Error bars represent 
SD. N=3 animals per group. 
CTRL = littermate c14/WT and/or c14/c14 animals depending on the breeding scheme. 
 
Discussion 
Since the initial discovery of ALS-associated mutations in FUsed in Sarcoma (FUS), 
attention has focused on the possibility that loss of one or more of the many functions of this 
essential regulatory protein in transcriptional regulation, pre-mRNA splicing, RNA processing, 
and RNA localization may lead to selective neurodegeneration in ALS and FTD. Previous work 
in our group among others has argued that FUS-mediated toxicity is a not a consequence of FUS 
loss of function, but a toxic gain of function related the disease-causing mutations. Here, using a 
series of knock-in mutant mice, we provide genetic evidence that the effect of disease-causing 
mutations on FUS activity are complex, leading to both loss and gain of function. We demonstrate 
that FUS-P517L (equivalent to human P525L) and the truncation mutation Δ14 – both highly 
pathogenic and associated with aggressive, juvenile-onset ALS – lead to a partial loss of function, 
each able to rescue the perinatal lethality of FUS deficiency only partially. Despite this loss of 
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function, genetic complementation experiments demonstrate that the toxicity of the mutant FUS 
protein is not primarily a consequence of FUS deficiency, but of a dose-dependent gain of function 
that leads to enhanced perinatal lethality unrelated to motor neuron degeneration. While gain vs. 
loss of function mechanisms cannot be fully distinguished here, our data demonstrate that FUS 
toxicity in vivo does not correlate with functional activity; FUS-P517L, while better able to rescue 
the FUS knockout phenotype, is more toxic than the less functional Δ14 mutant FUS protein. 
Furthermore, our data finds no correlation in vivo between the degree of cytoplasmic 
mislocalization and toxicity of mutant FUS; the truncated Δ14 protein, which completely lacks the 
PY-NLS domain, is present in the cytoplasm to a greater degree than FUS-P517L, but is less toxic, 
arguing against mislocalization as a primary determinant of FUS toxicity. This observation could 
be explained by the lack of the most C-terminal RGG domain in the Δ14 protein, which is involved 
in phase separation and interactions with other proteins, as well as RNA species. Consistent with 
that hypothesis, the Δ14 mutation causes less pronounced redistribution of RBPs into less soluble 
states and correspondingly, fewer associated changes in splicing in comparison to the P517L allele. 
Although the changes caused by ALS-related mutations in the interactome of FUS and their 
molecular consequences have yet to be elucidated, this suggests that ALS-associated FUS toxicity 
is mediated through aberrant FUS interactions. 
In heterozygous P517L and Δ14 mice, we observe selective, age-dependent motor neuron 
degeneration involving neuronal subpopulations – including fast-fatigable, large diameter (α) 
motor neurons that are preferentially vulnerable in ALS patients and in other mouse models of 
ALS. Using the conditional Δ14 (c14) allele, we were able to avoid the developmental toxicity 
observed in the homozygous P517L and Δ14 mutants, and the P517L/ Δ14 complex heterozygotes. 
Selective activation of the c14 mutant allele using ChAT-Cre in the P517L and Δ14 heterozygotes 
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generated mutants in which post-mitotic MNs express 2 copies of mutant FUS. Analysis of these 
conditional mutants reveals the dose-dependence of mutant FUS-mediated neurodegeneration 
through the accelerated loss of spinal MNs that nevertheless remains self-limited, and selective to 
the same vulnerable subpopulation of MNs involved in the P517L and Δ14 heterozygous mutants. 
Moreover, our analysis of the c14/c14 homozygous, ChAT-Cre animals in which only motor 
neurons express mutant Δ14 FUS was remarkably similar in phenotype to the Δ14/c14, ChAT-Cre 
mutants in which a single copy of the Δ14 FUS allele is expressed broadly in the animal, both in 
terms of the onset, time-course and extent of denervation and MN loss, but also with regard to the 
astrocyte and microglial proliferation that precedes MN degeneration. These data provide 
compelling genetic evidence that the onset and progression of MN loss in this mouse model of 
FUS-ALS is a cell autonomous process, and that to the degree to which other cells (e.g., astrocytes, 
microglia) contribute to neurodegeneration, this occurs independent of the expression of mutant 
FUS, with no evidence of a cell non-autonomous mechanism. 
The mechanism by which mutations in FUS, TARDBP (TDP-43) and other genes encoding 
RNA binding proteins cause neuronal degeneration in ALS remains unclear, but a compelling 
model of disease argues that toxicity involves the formation of abnormal assemblies or condensates 
of protein and RNA that arise as a consequence of a natural process of liquid-liquid phase 
separation (LLPS) that is critical for the normal, reversible functions of these regulatory proteins. 
The phase transition behavior of FUS and other ALS-associated proteins depends in large part on 
intrinsically disordered, prion-like domains that govern the interaction of FUS with itself or other 
partners. According to this model, disease-associated mutations in FUS alter the properties of the 
protein, leading to aberrant phase transitions – and both loss and gain of function - and increasing 
the proportion of total protein in condensates, leading to further consolidation and growth of 
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fibrillar structures that are the pathological hallmark of ALS. Although it is not possible to assess 
the phase or material properties of FUS in vivo, we are able to determine the solubility of FUS and 
its interactors in the brain and spinal cord of the FUS knock-in mutants, which may reflect the 
phase state and/or material properties of these proteins. We provide evidence that mutant FUS 
causes a dose-dependent increase in insoluble FUS and related proteins, along with aberrant 
splicing events related to the deficiency of those RBPs. While the observed levels of insoluble 
FUS/RBPs constitute a very small proportion of total FUS/RBPs, we hypothesize that the insoluble 
fraction corresponds to the formation of dense condensates that underlie the FUS-dependent 
toxicity we observe in this in vivo model of FUS-ALS. Supporting the disease relevance of this 
finding, the insolubility of FUS and other interacting proteins we observe in the FUS mice is also 
evident in the brain and spinal cord of a FUSP525L ALS patient, in which we find biochemical 
insolubility similar to that which we reported in the CNS of ALS/FTD patients with the C9orf72 
expansion, as well as sporadic cases that we found to be like C9. Together these data suggest an 
intriguing model of disease in which the insolubility of ALS-associated RBPs are interdependent 
– consistent with a biophysical model of heterotypic phase separation – where the 
insolubility/phase transition of a single disordered protein drives the insolubility/condensation of 
related proteins, leading to widespread loss of function and dysregulation of critical pathways, 




 : Targeting FUS with an antisense oligonucleotide as a 
therapeutic strategy for FUS ALS 
Our studies of the consequences of mutant FUS in this series of knock-in mice demonstrate 
a dose-dependent toxicity of mutant FUS that results in progressive degeneration of a select 
subpopulation of spinal MNs. This, together with our prior study using a conditional FUS knockout 
allele that showed that postnatal FUS deficiency in vivo does not result in MN degeneration96, 
suggest that lowering levels of FUS protein in vulnerable neurons could be an effective strategy to 
treat patients with ALS-FUS. To test this idea, we used ION363, an antisense oligonucleotide 
(ASO) directed against the 6th intron of FUS that was developed by Ionis Pharmaceuticals to target 
both mutant and wild type FUS transcripts. Ionis Pharmaceuticals performed a series of 
experiments to identify ASOs capable of effectively downregulating FUS levels in human or 
mouse cells. Select ASOs were subsequently validated in BAC-transgenic mice carrying the 
human FUS gene. ION363 was selected as one of the lead compounds targeting a sequence 
conserved between human and mouse FUS genes. 
ION363 administration leads to an efficient and sustained FUS knockout and 
reverses biochemical insolubility of RNA-binding proteins 
First, to evaluate the efficacy of ION363 in lowering FUS levels in vivo in the mouse, we 
administered a single 20 µg dose of ION363 via intracerebroventricular (ICV) injection to 
newborn (postnatal day 1, P1) wild type and P517/WT animals. Control animals received an 
identical injection of a non-targeted control (NTC) ASO. Western immunoblot analysis of brain 
and spinal cord of 1 month old ASO-treated animals demonstrated an overall decrease in both wild 




Immunostaining of spinal cords with an antibody154 to the modified backbone of the 
ION363- and NTC-ASOs demonstrated robust, predominantly nuclear signal in all cells, including 
MNs (Fig. 2-1A and 2-2A,B) at 1 and 4 months of age. However, by 6 months of age, analysis of 
anti-ASO immunostaining demonstrated near background levels of signal for both ION363 and 
the NTC ASO (Fig. 2-2A,B). The observed decrease in ION363 levels at 6 months of age was 





















A. Immunostaining of lumbar spinal cord sections of a 1-month-old ION363-treated animal with anti-ASO (red) and 
anti-ChAT (white) antibodies showing broad distribution of ION363 to MNs and non-neuronal cells and 
predominantly nuclear localization. 
B. Immunoblot probed with anti-FUS antibodies of brain, cervical or lumbar spinal cord protein lysates of 1-month-
old WT/WT and P517L/WT animals treated with non-targeted control (NTC) or anti-FUS oligonucleotide (ION363). 
Each band in a row represents a separate animal. 
C. Quantitation of total, WT, and P517L FUS protein levels shown in (B). Welch’s t-test was used for comparisons 




































































































A,B. Representative immunostaining of lumbar spinal cord sections from NTC- (A) or ION363- (B) treated animals 
with an anti-ASO antibody. The staining shows widespread nuclear and cytoplasmic distribution for NTC 
oligonucleotide and predominantly nuclear staining for ION363 at 1 and 4 months of age that disappears at 6 months. 
C. Immunoblot of lumbar spinal cord protein from 6-month-old WT/WT and P517L/WT animals treated with non-
targeted control (NTC) or anti-FUS oligonucleotide (ION363). Each lane represents a separate animal. 
D. Quantitation of FUS protein levels in lumbar spinal cord lysates from 6-month-old animals shown in (C). One-way 







































We next analyzed whether detergent insolubility of RBPs, the biochemical signature 
associated with FUS toxicity, is affected by ION363 treatment. Indeed, a decrease in the levels of 
TDP-43, hnRNP A1, hnRNP U, and UPF1 was observed in the detergent-insoluble fractions from 
ION363-treated versus NTC P517L/WT mice (Fig. 2-3A,B). Moreover, the ION363-induced 
decrease in wild type FUS protein in wild type mice also caused decreased partitioning of UPF1 
and hnRNPA1 into the detergent-insoluble fractions (Fig. 2-3A,B), suggesting wild type FUS-
dependent partitioning of some RBPs into detergent-insoluble subcellular compartments at a low 






















A. Immunoblot of brain sarkosyl insoluble fractions of 1-month-old WT/WT and P517L/WT animals treated with 
non-targeted control (NTC) or anti-FUS oligonucleotide (ION363). Each lane represents a separate animal. 
B. Quantitation of protein in sarkosyl insoluble fractions shown in (c), expressed as log-ratio of P517L/WT ION363 
for FUS-P517L and TDP-43 and as log-ratio of WT/WT NTC for all others. *P<0.05, **P<0.01 and ***P<0.001 
using one-way ANOVA with Tukey´s post hoc test for comparison of four groups and Welch’s t-test for two groups. 




































A single ION363 administration delays the onset of motor neuron degeneration in 
conditional compound heterozygous model 
The model of disease that we propose for ALS-FUS based on our animal studies predicts 
that the decrease in FUS protein levels – and associated decrease in detergent insolubility of FUS 
and related RBPs – caused by ION363 would mitigate the MN phenotype in the FUS mutant mice. 
To test this prediction, we injected newborn (P1) MN-P517L/Δ14 and wild type mice with a single 
ICV dose of 20 µg of ION363 or the NTC ASO, and quantified MN loss in all experimental 
animals at 4 and 6 months of age. At 4 months, the NTC-injected MN-P517L/Δ14 mice lost an 
average of 12% of all lumbar MNs (consistent with MN-P517L/Δ14 mice), but no MN loss was 
observed in ION363-treated MN-P517L/Δ14 (Fig. 2-4A). Similarly, injections of ION363 but not 
NTC completely prevented muscle denervation and microgliosis, both of which precede MN loss, 
in the MN-P517L/Δ14 mutants at 4 months (Fig. 2-4B,C). At 6 months of age, when ION363 
concentration decreases and FUS levels normalize (Fig. 2-2C,D), muscle denervation and 
microgliosis increased in ION363-treated MN-P517L/Δ14 mice to levels intermediate between 
those of NTC-injected MN-P517L/Δ14 and wild type mice, suggesting the delayed onset of the 
disease pathology in this model (Fig. 2-4B,C). Nevertheless, no MN degeneration was observed 
in ION363-treated MN-P517L/Δ14 mice at 6 months after treatment (Fig. 2-4A).  
These pre-clinical data demonstrate that a single perinatal injection of ION363 results in a 
robust and persistent decrease in FUS protein levels for more than 4 months, and that while the 
ASO perdures in the spinal cord, the onset of gliosis is delayed and MN loss prevented, 
demonstrating the therapeutic potential of FUS silencing – and of this specific FUS-ASO - in the 
















A. Numbers of ChAT positive motor neurons at lumbar levels 4 and 5 in NTC-treated FUS WT-expressing CTRL 
(black), ION363-treated FUS WT-expressing CTRL (gray), NTC-treated MN-P517L/Δ14 (dark red), and ION363-
treated MN-P517L/Δ14 (light red) animals normalized to the NTC-treated FUS WT-expressing CTRL. 
B. Percentage of fully innervated NMJs in the tibialis anterior muscles in NTC-treated FUS WT-expressing CTRL 
(black), ION363-treated FUS WT-expressing CTRL s (gray), NTC-treated MN-P517L/Δ14 (dark red), and ION363-
treated MN-P517L/Δ14 (light red) animals. 
C. Density of Iba1-positive microglial cells at lumbar levels 4 and 5 in NTC-treated FUS WT-expressing CTRL 
(black), ION363-treated FUS WT-expressing CTRL (gray), NTC-treated MN-P517L/Δ14 (dark red), and ION363-
treated MN-P517L/Δ14 (light red) animals. 
*P<0.05, **P<0.01 and ***P<0.001 using two-way ANOVA with Tukey´s post hoc test. Error bars represent SD. 
N=3 animals per group.  



























































ION363 treatment reduces FUS levels and reverses biochemical insolubility of RBPs 
in the first treated ALS FUS patient 
ION363 targets an intronic sequence identical in mouse and human and therefore 
represents a promising therapeutic strategy to decrease FUS toxicity in ALS patients. With this 
rationale, we successfully submitted a single patient, individual expanded access (“compassionate 
use”) Investigational New Drug Application (IND) application to the US Food and Drug 
Administration (FDA) to treat an ALS patient (JH) with a FUSP525L mutation. Under this 
experimental, first-in-human protocol, JH received ascending, intrathecal (IT) doses of ION363, 
starting with 20 mg up to a maximum monthly dose of 120 mg IT for a total of 12 infusions over 
10 months. Treatment with ION363 began more than 6 months after clinical onset, by which time 
JH’s disease had progressed significantly to the point that the patient was no longer ambulatory 
and required non-invasive ventilatory support (ALSFRS-R score of 17). JH tolerated the 
experimental protocol well, without any serious adverse events, but the disease progressed through 
the course of therapy (Fig. 2-5), and the patient died of complications of ALS 18 months after 
disease onset, nearly 1 year after initial treatment with ION363. A full autopsy including 













At the time of definitive diagnosis, JH had ALSFRS-R score of 41 (out of 48). Over the course of the next three 
months her condition rapidly deteriorated and her ALSFRS-R score dropped to 17 by the time she received the first 
ION363 dose. During the next nine months, she received twelve ION363 administrations total. After the 12th dose, the 
patient decided to discontinue treatment and died two months later. 
 
Immunohistochemical staining of the spinal cord and brain sections with an antibody 
specific to the oligonucleotide backbone of ION363 revealed diffuse, predominantly cytoplasmic 
puncta within neurons (Fig. 2-6A, Fig. 2-7). This pattern suggests broad distribution of ION363 
throughout the patient’s CNS, and that at least 2 months after the last therapeutic infusion, the 
ASO perdures in the treated brain and spinal cord. 
Western blot analysis of brain stem tissue from JH compared to normal control tissue and 
tissue from a different untreated ALS-FUSP525L patient (Fig. 2-6B) showed a dramatic reduction 
of both total and P525L mutant FUS protein to nearly undetectable levels, demonstrating that as 
in the mouse, ION363 can effectively silence FUS in humans. In addition, as we observed in the 
MN-P517L/Δ14 mutant mice, this ION363-induced downregulation of FUS also resulted in a 
decrease in the levels of sarkosyl-insoluble FUS and other RBPs, including TDP43, hnRNP A1, 
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hnRNP U, and UPF1 (Fig. 2-6C), but no change in the total protein levels of these RBPs, 















A. Anti-ASO immunohistochemical staining of FFPE sections of lumbar spinal cord from a non-ALS control (top) 
and lumbar (middle) and cervical (bottom) spinal cord from ION363-treated ALS-FUSP525L patient. Scale 
bar=100µm at 10x and 20µm at 40x. 
B. Immunoblot of brainstem tissue from a non-ALS control, ALS-FUSP525L control patient, and ION363-treated 
ALS-FUSP525L patient probed with antibodies against non-overlapping epitopes of FUS. 
C. Immunoblot of equal volumes of sarkosyl insoluble fractions from brain stem tissue from a non-ALS control, ALS-
FUSP525L control patient, and ION363-treated ALS-FUSP525L patient probed with antibodies against total FUS 
























Anti-ASO immunohistochemical staining of FFPE sections of motor cortex (BA4) from a non-ALS control 
(left) and ION363-treated ALS-FUSP525L patient (right). Scale bar=200µm at 4x and 20µm at 40x 
  
ASO antibody staining 
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ION363 treatment ameliorates pathological hallmarks of FUS ALS in the first 
treated ALS FUS patient 
Based on the treatment of a single patient, it is not possible to determine if the silencing of 
FUS had any effect on the course of disease in this case. However, to look for evidence in support 
of clinical benefit, we asked if the downregulation of FUS had any effect on FUS pathology in the 
ASO-treated brain. Immunohistochemical staining with a commercial antibody (“FUS-Total”) 
showed predominantly nuclear localization of FUS in the spinal cord of the normal control and, in 
the untreated P525L tissue, numerous, abnormal, cytoplasmic and intranuclear aggregates within 
neurons and other cell types - the pathological hallmark of ALS-FUS. In striking contrast, we 
observed no nuclear FUS staining in the ION363-treated P525L spinal cord, and very sparse FUS-
positive aggregates in the remaining motor neurons (Fig. 2-8, 2-9). In the motor cortex of the 
P525L control brain, FUS localization was also predominantly nuclear and widespread 
pathological inclusions were especially prominent in layer V cells. However, in the motor cortex 
of the ION363-treated P525L case, immunohistochemical staining revealed no nuclear FUS and 
only scant aggregates within layer V (Fig. 2-10). Using a P525L-specific polyclonal antibody, a 
similar pattern was observed in both brain and spinal cord (Fig. 2-11). Finally, a P525L-specific 
mouse monoclonal antibody showed a preferential affinity for mutant FUS-positive aggregates in 
the anterior horn of the untreated P525L spinal cord. However, consistent with the previous 
observations, no abnormal FUS staining was observed in the spinal cord or motor cortex of the 


















Low-power immunohistochemical images of FFPE sections of lumbar spinal cord from a non-ALS control (left), 
ALS-FUSP525L control patient (middle), and ION363-treated ALS-FUSP525L patient (right) stained with an 
antibody against total FUS (FUS-Bethyl[400-450], top row), P525L-specific mouse monoclonal antibody reactive to 


















High-power immunohistochemical images of FFPE sections of lumbar spinal cord from a non-ALS control (left), 
ALS-FUSP525L control patient (middle), and ION363-treated ALS-FUSP525L patient (right) stained with an 
antibody against total FUS (FUS-Bethyl[400-450], top row), P525L-specific mouse monoclonal antibody reactive to 






















Immunohistochemical staining of FFPE sections of motor cortex (BA4) from a non-ALS control (left), ALS-
FUSP525L control patient (middle), and ION363-treated ALS-FUSP525L patient (right) with an antibody against 






















Immunohistochemical staining of FFPE sections of motor cortex (BA4) from a non-ALS control (left), ALS-
FUSP525L control patient (middle), and ION363-treated ALS-FUSP525L patient (right) with P525L-specific guinea 























Immunohistochemical staining of FFPE sections of motor cortex (BA4) from a non-ALS control (left), ALS-
FUSP525L control patient (middle), and ION363-treated ALS-FUSP525L patient (right) with P525L-specific mouse 




Overall, these data demonstrate that ION363 effectively suppresses FUS expression 
throughout the CNS, reverses biochemical insolubility of RBPs associated with mutant FUS 
toxicity, and reduces the burden of FUS pathological aggregation in surviving, vulnerable neurons 
in the brain and spinal cord. Together with the pre-clinical data from the FUS-ALS knock-in mouse 
models of disease, this first neuropathological study of an ALS-FUS patient treated with ION363 
strongly supports FUS silencing as a promising approach to delay or prevent disease onset in pre-
symptomatic carriers of ALS-associated FUS mutations, and as an early therapeutic intervention 
in ALS-FUS patients155. 
ION363 reduces clinical markers associated with ALS progression 
Several more ALS-FUS patients have received ION363 treatment as part of the 
investigator-lead study conducted through the Expanded Access Program (EAP). Under this 
program, individual expanded access IND applications were submitted to FDA to allow ION363 
administration to each individual patient with ALS-FUS. Over the course of the EAP, more than 
twelve patients had received at least one dose ION363 before May 2021, when these patients were 
enrolled in a global phase 3 pivotal trial sponsored by Ionis Pharmaceuticals to evaluate the 
efficacy, safety, pharmacokinetics and pharmacodynamics of ION363 (NCT04768972) in patients 
with ALS-FUS155. 
The major problem for clinical trials in ALS is the lack of reliable biomarker that could be 
used to evaluate the disease activity156. Most clinical trials use survival (or time to tracheostomy) 
or ALSFRS-R (revised ALS Functional Rating Scale) as the primary outcome157. These outcomes 
require prolonged monitoring to draw any conclusions regarding the efficacy of the investigational 
therapeutic intervention. Although numerous potential biomarkers have been investigated for this 
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role, including TDP-43, SOD1, C9orf72 translation products, inflammatory cytokines and others, 
neurofilament proteins are considered the most promising biomarkers to date157-160. 
Neurofilaments (NFs) are intermediate filaments present in the cytoplasm of neuronal cells. 
NFs are especially abundant in axons where they are aligned in parallel fibers along the axonal 
axis. Neurofilaments provide structural support for the axons and affect their diameter which 
influences axonal conduction velocity. Three major proteins comprising NFs were originally 
identified and named based on their molecular weight, NF light (NF-L), medium (NF-M), and 
heavy (NF-H)161. Subsequently, additional NF components were identified, including α-
internexin162 and peripherin163. 
As major structural components of neurons, NFs are present in CSF at very low levels 
under physiological conditions, however, their levels increase dramatically in the presence of 
neuronal damage. Thus, NF-L was reported to be elevated in patients with a variety of neurological 
disorders, including cerebral infarction164, vascular dementia164,165, frontotemporal dementia165,166, 
Alzheimer’s disease165,166, dementia with Lewy bodies166, supranuclear palsy166, multiple 
sclerosis164,167, and ALS164,166,168. In many of these studies higher NF levels also correlated with 
more severe disease and lower survival, suggesting that NF could be used as a prognostic marker. 
Moreover, NFs levels in blood highly correlated with their levels in patients’ CSF which makes it 
possible to use a blood test instead of a lumbar puncture in clinical settings. 
In studies dedicated to ALS, both NF-L and pNF-H were found to be significantly elevated 
in patients’ CSF and blood and correlate with the disease progression rate and ALSFRS-R 
decline169-171. Recent longitudinal studies of NFs as biomarkers in pre-symptomatic carriers of 
ALS-causative genes showed that elevated NF levels could be detected as far back as 6-12 months 
or even several years before the appearance of ALS-defining symptoms172,173Importantly, NF 
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levels were shown to continue to rise until they stabilize approximately 6 months after the onset 
of the symptoms. Other longitudinal studies of NFs in ALS patients have shown that their levels 
are fairly stable over the course of the disease170,171. All these data suggest that NF might be a 
useful pharmacodynamic biomarker to estimate neuronal damage and response to therapeutics in 
ALS, although more multicenter studies are needed to confirm that. This is also supported by 
preclinical studies of ALS showing a decrease in pNF-H levels in transgenic SOD1 G93A mice in 
response to a treatment with anti-SOD1 oligonucleotides174. Moreover, NF-L was also reported to 
decrease in response to a disease-modifying therapy in patients with multiple sclerosis167 
supporting its role as a general marker of neuronal/axonal damage. 
We measured the levels of NF-L and pNF-H in CSF and plasma from six patients received 
at least four doses of ION363 by the time of analysis. We observed a trend towards the decrease 
of the levels of both biomarkers in both CSF and plasma, especially in long-term treated patients 
(Fig. 2-13). These data suggest a potential clinical benefit of the treatment aimed at reducing the 
































































A,C. Longitudinal CSF (A) and plasma (C) NF-L concentration in patients with ALS FUS receiving ION363 
treatment.  
B,D. Longitudinal CSF (B) and plasma (D) pNF-H concentration in the same patients. 
Patient 5 is an asymptomatic (AS) twin of patient 4. Mutation G515_E516insD is previously not reported as causative 
in ALS but predicted to be pathogenic. 
Each colored line represents a single patient with the indicated FUS mutation. Total of six patients who received at 
least four ION363 administrations were included in the analysis. 
 
Although it is hard to make a conclusion about a clinical efficacy of a drug without a 
placebo control group in the current patient sample, the ongoing phase 3 clinical study of ION363 
in patients with ALS-FUS is specifically designed for that purpose. All patients treated under the 
EAP will be transferred to the Ionis trial and will continue to receive ION363 in an open-labeled 
arm of the study. Future plans involve finishing the analysis of clinical data and NF-L and pNF-H 







The saturation concentration (Csat) of proteins that undergo LLPS is the critical 
concentration required for phase separation. ALS-associated mutations in FUS lower the Csat of 
the protein in vitro, leading to aberrant phase transition and likely, to associated toxicity in vivo. 
Our demonstration of dose-dependent toxicity of mutant FUS the mouse is consistent with a 
disease model that involves aberrant phase transition and the formation of abnormal assemblies 
that are toxic to motor neurons. This model suggests a therapeutic approach to FUS-ALS by which 
reduction of FUS levels below the Csat could alter the dynamics of LLPS and aggregation, and 
thereby delay or prevent disease onset, or slow (or halt) disease progression once it has begun. 
Using an anti-sense oligonucleotide (ASO) that targets the FUS transcript in a non-allele-specific 
manner (ION363), we demonstrate that a single ICV injection of the therapeutic into the newborn 
mice results in the marked (50-80%) reduction in total FUS (WT and mutant) and prevents motor 
neuron degeneration for as long as the ASO continues to silence FUS expression in the CNS. 
Indeed, 4 months after injection of the ASO, when we consistently see loss of 10-15% of all L4/5 
lumbar motor neurons, there is virtually no evidence of neurodegeneration, or the gliosis and 
muscle denervation that precedes it. At 6 months, when ASO levels are no longer detectable and 
FUS levels have returned to normal, we begin to see astro- and micro-gliosis along with TA 
denervation, but still no evidence of motor neuron loss. These data support the use of FUS-
lowering therapeutic intervention as a preventative treatment strategy for ALS FUS. However, in 
clinical settings, most patients present after the onset of symptoms. Therefore, performing 
experiments when FUS mutant mice are treated with ION363 after developing the first signs of 
the disease would more faithfully replicate the treatment in clinical settings. However, the mild 
total MN loss phenotype (~20%) observed in these animals makes it challenging to detect a partial 
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rescue. Focusing specifically on vulnerable MN subpopulations and limiting the analysis to only 
α-MNs or MMP9+ MNs would increase the dynamic range to 30-40% MN loss and might help us 
detect partial MN loss rescue in these settings. 
With support of these pre-clinical data, we were able to introduce ION363 into the clinic 
to treat an ALS patient with a FUSP525L mutation under an FDA-approved, individual patient, 
expanded-access (“compassionate use”) protocol. The patient received repeated intrathecal 
infusions of the FUS-ASO over a 10-month period, without any related, serious adverse events, 
but unfortunately died of complications of ALS. Analysis of post-mortem brain and spinal cord 
revealed a profound reduction in both WT and mutant FUS protein to levels that were barely 
detectable immunohistochemically, or by Western analysis. Strikingly, the FUS-positive neuronal 
cytoplasmic inclusions that are a hallmark of FUS-ALS and prominent in the surviving motor 
neurons of the untreated FUSP525L tissue we analyzed were rarely observed in the ASO-treated 
case. These data demonstrate the efficacy of intrathecal delivery of ION363 in lowering the levels 
of the pathogenic FUS protein, and the tolerance of our patient to prolonged reduction in FUS 
levels in the CNS. Moreover, this first-in-human study of this anti-sense therapeutic demonstrates 
that FUS silencing leads to a reduction in the burden of FUS pathology in the FUS-ALS brain, 
either by inhibiting FUS aggregation or by altering the dynamics of aggregate formation in a way 
that allows proteostatic mechanisms to restore balance in vulnerable neurons. Importantly, JH did 
not report any serious adverse effects during the 10 months of receiving ION363 treatment. At the 
time of writing this dissertation, 12 patients have received ION363 as part of EAP with no serious 
side effects observed. The longest treatment period is approaching two years for one of the enrolled 
patients. ION363 tolerability profile and lack of observed side effects during short-term treatment 
over several months eases some concerns regarding potential toxicity associated with FUS 
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downregulation. Mice in which FUS was genetically eliminated postnatally develop generalized 
seizures that are frequently fatal, raising serious concern for a similar problem in human subjects 
treated long-term with a FUS-lowering ASO. However, unlike the genetic knockout experiment, 
ASO treatment results in incomplete reduction of FUS, leaving low levels of residual functional 
FUS protein that might be sufficient to prevent severe side effects associated with complete loss 
of FUS. The apparent safety of ION363 may reflect a less critical function for FUS in adults 
beyond its requirement in early development. Regardless, safety concerns will require careful 
clinical observation of all patients treated long-term with ION363 through expanded access 
programs or in clinical trial. 
While treatment with ION363 may have come too late to change the clinical outcome in 
our first patient, the neuropathological findings of reduced FUS pathology, and evidence of 
decreased NF-L and pNF-H levels in CSF and plasma from a subset of treated patients, together 
with the mouse data showing a profound effect of ION363 on the motor neuron phenotype in FUS 
knock-in mice, offer encouragement that ongoing clinical studies (NCT04768972) will 
demonstrate that this therapeutic effectively slow disease progression in symptomatic FUS-ALS 
patients, and in future studies, delays or prevents the onset of disease in pre-symptomatic carriers 




 : Other modifiers of FUS toxicity  
Knock-in mouse models of FUS ALS including the conditional compound heterozygous 
model described in Chapter 1 represent a highly disease relevant model with a robust and 
consistent phenotype that make this a highly tractable system in which to study disease 
mechanisms and to evaluate potential modifiers of FUS toxicity. 
hnRNP U 
HnRNP U is a ubiquitously expressed, predominantly nuclear RNA-binding protein, and a 
member of the heterogeneous nuclear ribonucleoproteins (hnRNP) protein family. It is considered 
to be a major splicing regulator175-177, and has also been shown to regulate gene expression178,179, 
act as a critical component of the X-chromosome inactivation180, and interact with a centromere 
protein CENP-W to increase its stability during mitosis181. 
Recent genetic studies have linked de novo mutations in hnRNPU gene to 
neurodevelopmental abnormalities including early-onset epilepsy and intellectual disability182,183. 
HnRNP U has also been mechanistically implicated in ALS as it was shown to directly bind TDP-
43 and ameliorate TDP-43 overexpression-caused neurotoxicity184. Although hnRNP U-FUS 
interaction has been reported148, the exact functional consequences of this interaction in normal or 
in the context of ALS-FUS have not been studied. 
Previous work in our laboratory185 identified hnRNP U as a potential mediator of FUS 
toxicity. In those experiments, hnRNP U was found to strongly interact with FUS in a mutation-
dependent manner. However, those experiments were conducted using transgenic mice96 that tend 
to express mutant FUS at a significantly higher level than WT FUS. These differences alone could 
explain the observed selective interaction between mutant FUS and hnRNP U. HnRNP U has also 
been reported to interact with WT FUS148,151,186, however, most of independent studies involved 
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overexpression of FUS in cultured cell lines that might have resulted in protein-protein interactions 
that do not occur under physiological conditions. In order to validate these findings in a more 
relevant model, we repeated the FUS co-immunoprecipitation experiments in FUS knock-in mice 
and confirmed the interaction between FUS and hnRNP U (Fig. 3-1A) and another previously 
reported FUS interactor, hnRNP A1. Neither of these interactions seemed to depend on FUS 
mutation as the amount of protein co-immunoprecipitated along with FUS did not differ between 
WT. P517L/WT and P517L/P517L animals. 
Nevertheless, it is possible that functional sequestration of hnRNP U and other RBPs 
occurs not as a consequence of increased affinity of mutant FUS to certain proteins, but due to 
FUS-mediated LLPS and aggregation. As our previous studies described in Chapters 1 and 2 
support this hypothesis, we therefore decided to investigate the role of hnRNP U in MNs. 
Motor neuron-specific hnRNP U knockout results in neurodegeneration with selective 
vulnerability 
Previous studies185 indicate that hnRNP U haploinsufficiency is maladaptive and results in 
a lower than expected Mendelian birth ratio and a decreased body weight. Initial observations of 
the hnRNP U KO/Fl; ChAT-Cre mice revealed denervation in a few analyzed muscles (diaphragm, 
tongue, and TA) without significant MN loss in lumbar spinal cord at L4-L5 levels at 4 weeks of 
age when these animals die. For the subsequent experiments, we decided to analyze the phenotype 
of hnRNP U Fl/Fl; ChAT-Cre (hnRNP U MN-KO) animals to avoid additional maladaptive effects 
of hnRNP U haploinsufficiency. Unlike hnRNP U KO/Fl; ChAT-Cre, hnRNP U MN-KO animals 
are born at Mendelian ratios, have normal birth weights, and are indistinguishable from littermate 
controls until after 3 weeks of age when they develop progressive weakness, rapidly lose weight, 
and die around P28. 
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Analysis of MNs in lumbar spinal cord at L4-L5 levels at the time of death in these animals 
revealed preferential loss of α- and sparing of γ-MNs (Fig. 3-1D-F), consistent with the selective 
vulnerability characteristic of ALS144. Interestingly, these mice also showed subtotal loss of 
preganglionic neurons of the autonomic nervous system, including the intermediolateral nucleus 
(sympathetic) at thoracic spinal levels (Fig. 3-2A) and n. dorsalis nervi vagi (parasympathetic) in 
the medulla oblongata (X cranial nucleus). 
Denervation analysis of lower hindlimb muscles, however, showed preferential 
involvement of flexors (soleus and plantaris) and resistance of extensors (TA, EDL). Muscles 
innervated from the cervical spinal cord (diaphragm) and hypoglossal (XII) cranial nucleus 
(tongue) were also affected similarly to what was observed in hnRNPU KO/Fl; ChAT-Cre mice185. 
Analysis of extraocular muscles (EOMs) revealed that both m. rectus lateralis (n. abducens, VI) 
and m. obliquus superior (n. trochlearis, IV) are similarly affected. However, only two muscles, 
m. rectus superior and m. rectus inferior, innervated from the oculomotor nucleus (III) had 
significant denervation while the remaining three (m. rectus medialis, m. obliquus inferior, and m. 
levator palpebrae superioris) showed no signs of denervation (Fig. 3-1C). 
Although MN-specific hnRNP U KO does not result in the same pattern of differential 
vulnerability characteristic to ALS, it nevertheless represents an unexpected observation of 
selective degeneration of certain pools of MNs in response to the elimination of a critical protein, 
ranging from complete loss (autonomic CNS) to preferential vulnerability (extensors) to sparing 
(flexors). Moreover, EOMs analysis also shows selective involvement of MN subtypes from the 
same cranial nucleus (III). These data suggest that functionally distinct MNs show a differential 
dependence on the function of hnRNP U. Considering the number and complexity of FUS 
interactions through its prion-like domain, deficiency of specific RBP interactors -each with their 
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own functional redundancy, cooperativity, and interdependence77 - could potentially explain the 






















A. FUS IP showing comparable co-immunoprecipitation of RBPs hnRNP U and hnRNP A1 with FUS irrespective of 
P517L mutation. 
B. Body weight growth of hnRNPU MN-KO animals in comparison to littermate controls. N=5-9 per group. 
C. Percentage of completely denervated NMJs in various skeletal muscles from end-stage hnRNPU MN-KO animals. 
TA = m. tibialis anterior, EDL = m. extensor digitorum longus, Extraocular muscles (EOMs): RL = m. rectus lateralis, 
RS = m. rectus superior, RI = m. rectus inferior, RM = m. rectus medialis, m.LPS = m levator palpebrae superioris, 
OI = m. obliquus inferior, OS = m. obliquus superior. Roman numerals indicate cranial nuclei innervating EOMs. 
*P<0.05, **P<0.01 and ***P<0.001 using two-way ANOVA with Sidak´s post hoc test versus controls all having 0% 
denervation (not shown). 
D-F. Numbers of ChAT positive α- (E), γ- (F), or all (D) motor neurons at L4-L5 levels of the spinal cord in 
hnRNPU MN-KO (red) and control (black) animals normalized to the controls. Controls = littermate hnRNPUfl/wt 
animals. Statistical differences were determined using Welch’s t-test. 














































A. Thoracic spinal cord sections from an hnRNP U MN-KO (right) and control (left) animals. Arrows point to 
intermediolateral nuclei containing preganglionic neurons of the sympathetic nervous system. 
B. Brainstem sections at the level of hypoglossal nuclei from an hnRNP U MN-KO (right) and control (left) animals. 






Viral overexpression of hnRNP U does not rescue FUS toxicity 
Considering the observed increase in insolubility of hnRNP U in FUS knock-in animals 
and patients with ALS-FUS (Chapter 1) and pathogenicity of hnRNP U loss described in this 
Chapter, we next investigated whether AAV9-mediated overexpression of hnRNP U in MN-
P517L/Δ14 animals can prevent or delay MN loss in this model. We administered either hnRNP U- 
or GFP-encoding virus to newborn MN-P517L/Δ14 and control animals via ICV route and 











Numbers of ChAT positive motor neurons at lumbar levels 4 and 5 in GFP-treated FUS WT-expressing CTRL (black), 
hnRNP U-treated FUS WT-expressing CTRL (green), GFP-treated FUS mutant (MN-P517L/Δ14) (red), and hnRNP 
U-treated FUS mutant (MN-P517L/Δ14) (blue) animals normalized to the GFP-treated FUS WT-expressing CTRL. 
*P<0.05, **P<0.01 and ***P<0.001 using one-way ANOVA with Tukey´s post hoc test. Error bars represent SD. 
N=3-5 animals per group.  
CTRL = littermate c14/c14 animals. 
 
At 6 months of age, AAV9-hnRNP U-injected MN-P517L/Δ14 animals had ~18% MN 
loss at L4-L5 levels of lumbar spinal cord similar to ~17% in AAV9-GFP-treated MN-P517L/Δ14 







Our studies suggest that ALS-associated FUS mutation result in increased propensity of 
FUS to undergo LLPS along with other FUS-interacting RBPs resulting in multi-RBP deficiency 
and numerous alterations in RNA metabolism. The precise biological role is not known for many 
RBPs, whose binding motifs and target preference can be greatly affected by their interacting 
partners. Many hnRNPs have shown a great degree of overlap between their targets77 resulting in 
functional redundancy on one hand, and cooperative or antagonistic regulation of certain splicing 
events on the other. The fact that hnRNPs also cross-regulate by reciprocal binding to the encoding 
transcripts adds to the complexity of RNA dysregulation as a result of multi-RBP deficiency. Our 
data with hnRNP U suggests that correcting the deficiency of a single RBP by viral overexpression 






UPF1 is a critical component of nonsense-mediated mRNA decay (NMD), a surveillance 
mechanism that detects aberrantly spliced transcripts containing premature stop codons. 
Approximately 5-30% of all transcripts contain a premature stop codon (PTC), and some of these 
may produce truncated or aberrant proteins187-189. The need to manage these abnormal transcripts 
is reflected in the observation that all eukaryotic organisms examined so far have NMD machinery. 
Mechanistically, this process is tied to the first round of translation of a transcript during which 
the ribosome displaces exon-junction complexes (EJC) remaining after the mRNA splicing 
event190-192. If a ribosome reaches a stop codon more than ~50 nucleotides upstream from the last 
EJC, UPF1 and its kinase together with the two termination factors eRF1 and eRF3 are recruited 
to form the SMG-1-Upf1-eRF1-eRF3 complex (SURF)193. UPF1 and SMG1 then form a bridging 
complex to EJC where UPF2 directly interacts with CH domain of UPF1 promoting 
phosphorylation of UPF1 by SMG1194,195. This event triggers the remodeling of the PTC-
recognizing SURF complex into mRNA decay inducing complex (DECID) with DHX34 helicase 
acting as a scaffold in this process196,197. Additional factors promoting and executing decay, 
including SMG6 and SMG5/7, are subsequently recruited and the transcript is degraded198-203. 
Although its functional role in the pathogenesis of the disease has not yet been established, 
NMD has been implicated in ALS. ECM32, a yeast UPF1 homolog, was identified as a modifier 
of FUS overexpression toxicity in yeast204 and both human UPF1 and UPF2 were shown to 
ameliorate FUS toxicity in that yeast model, likely through NMD upregulation. Subsequently, 
UPF1 was shown to rescue ALS-associated toxicity of mutant FUS and TDP-43 but not SOD1 in 
primary neurons205 and its effect was significantly diminished in the presence of NMD inhibitors. 
AAV9-mediated overexpression of UPF1 was reported to be protective in a rat model of TDP-43 
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toxicity induced by its viral overexpression206. However, another recent study has found that 
overexpression of mutant FUS in N2a cells results in impairment of autoregulation of NMD 
components with upregulation of pro-NMD factors such as UPF1 and UPF3b and downregulation 
of NMD-inhibiting factor UPF3a leading to enhanced NMD activity207. A similar pattern was 
observed in patient-derived fibroblasts207. Another study found differential gene expression 
changes in hippocampal neurons from transgenic mice overexpressing R514G or WT FUS 
including upregulation of pro-NMD factors UPF3b and SMG7, however, functional activity of 
NMD was not analyzed208. These studies support the interconnection between FUS toxicity and 
NMD, however, they do not allow a definitive conclusion on the exact contribution of NMD to 
neurodegeneration. Since the cell models used in these studies do not develop FUS pathology and 
undergo FUS-dependent degeneration, a compensatory upregulation of NMD could not be ruled 
out. 
UPF1 is one of a few shared interactors of several RBPs involved in the pathogenesis of 
ALS, including FUS, TDP-43, and ATXN2186, and is a key regulator of numerous mRNA decay 
pathways209. Consistent with the involvement of multiple RBPs in the C9orf72 hexanucleotide 
repeat expansion (HRE) pathology associated with global changes in RNA metabolism107,114, 
UPF1 was repeatedly shown to be protective against C9orf72-HRE toxicity210-212. However, given 
the multiple functions of UPF1, it has not been established whether this protection is mediated by 
NMD. While some studies report transcriptional changes in brain and spinal cord samples from 
C9orf72 and some sporadic ALS patients consistent with NMD deficiency210, others do not213. 
Similarly, studies of the effects of overexpressed dipeptide repeats translated from C9orf72-HRE 
on NMD and UPF1 overexpression in these settings report opposing results211,212. 
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Our data described in Chapters 1 and 2 showed an increase in sarkosyl-insoluble UPF1 in 
FUS knock-in animals and patients with ALS-FUS suggesting its deficiency and the resulting 
insufficiency of the NMD pathway. According to this hypothesis, one would expect viral 
overexpression of UPF1 in MNs of conditional compound heterozygous animals to ameliorate 
mutant FUS-associated toxicity and prevent MN loss. 
Viral overexpression of UPF1 prevents motor neuron loss in conditional compound 
heterozygous model 
To test this prediction, newborn MN-P517L/Δ14 or control animals were injected with 
AAV9 vectors encoding either GFP or UPF1, as in previously described experiments. 
At 8 months, the GFP-injected MN-P517L/Δ14 mice lost an average of 17% of all lumbar 
MNs (consistent with MN-P517L/Δ14 mice), but no MN loss was observed in UPF1-treated MN-
P517L/Δ14 (Fig. 3-4A). Similarly, UPF1- but not GFP-AAV9 completely prevented microgliosis 
which precedes MN loss (Fig. 3-4B). UPF1-AAV9 injection also prevented the development of 
motor deficits in forelimb and hindlimb grip strength in MN-P517L/Δ14 mice that developed at 4-
6 months of age in GFP-AAV9-injected MN-P517L/Δ14 animals. 
Although the exact mechanism by which UPF1 rescues FUS toxicity has not been 
established, these preclinical data suggest UPF1 gene therapy as a potential therapeutic for ALS-
FUS. UPF1 is critical for NMD, but it was also shown to regulate other mRNA decay pathways, 
including staufen-mediated decay214, replication-dependent histone mRNAs decay215, 
glucocorticoid receptor-mediated mRNA decay216, and others. UPF1 also exerts other non-NMD 
effects, such as on DNA synthesis during replication or repair217, telomere maintenance218, protein 
degradation due to its E3 ubiquitin-ligase activity219, and nuclear export of RNA220. Future 
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experiments will aim to elucidate the role of NMD in healthy and ALS-FUS MNs and whether the 
observed protective effect of UPF1 in the ALS-FUS mouse model is due to its NMD function. 
To implicate NMD in the pathogenesis of ALS-FUS independent of UPF1, we took a 
mouse genetic approach using the UPF2Flox mouse allele221 to impair NMD selectively in MNs in 
wild-type and FUS mutant mice. UPF2Flox/Flox; ChAT-Cre mice develop normally, however, they 
exhibit an overt motor phenotype characterized by a fine tremor and increased mortality after 6-8 
months of age. At the time of writing this dissertation, the oldest mice approach 1 year, and 
experiments are planned to complete a functional characterization of the observed motor 
phenotype in these animals and assess whether they develop denervation and/or MN loss. We are 
also planning to cross these mice to P517L/C14 background to see whether elimination of NMD 
specifically in MNs exacerbates FUS toxicity and accelerates MN loss phenotype. Lastly, in the 
P517L/C14; UPF2Flox/Flox; ChAT-Cre animals where NMD cannot be restored by UPF1 
expression, we will test whether viral overexpression of UPF1 still mitigates FUS toxicity as it did 
in the P517L/C14; ChAT-Cre controls. If the mechanism of UPF1 action is mediated by NMD 
rather than by any other reported UPF1 function, we would predict that the protective effect would 
be lost. In addition, we will use a combination of single cell sequencing, laser-capture 
microdissection and mRNA sequencing and spatial transcriptomics to analyze alterations in 
mRNA metabolism in different animal cohorts, including FUS mutant (MN-P517L/Δ14), NMD-
deficient, UPF1-treated animals, and corresponding controls to identify specific molecular 




















A. Numbers of ChAT positive motor neurons at lumbar levels 4 and 5 in GFP-treated FUS WT-expressing CTRL 
(black), UPF1-treated FUS WT-expressing CTRL (blue), GFP-treated FUS mutant (MN-P517L/Δ14) (red), and 
UPF1-treated FUS mutant (MN-P517L/Δ14) (green) animals normalized to the GFP-treated FUS WT-expressing 
CTRL. 
B. Density of Iba1-positive microglial cells at lumbar levels 4 and 5 in GFP-treated FUS WT-expressing CTRL 
(black), UPF1-treated FUS WT-expressing CTRL (blue), GFP-treated FUS mutant (MN-P517L/Δ14) (red), and 
UPF1-treated FUS mutant (MN-P517L/Δ14) (green) animals normalized to the GFP-treated FUS WT-expressing 
CTRL 
C. Forelimb (left) and hindlimb (right) grip strength of the GFP-treated FUS WT-expressing CTRL (black), UPF1-
treated FUS WT-expressing CTRL (blue), GFP-treated FUS mutant (MN-P517L/Δ14) (red), and UPF1-treated FUS 
mutant (MN-P517L/Δ14) (green) animals normalized to the GFP-treated FUS WT-expressing CTRL. *P<0.05, 
**P<0.01 and ***P<0.001 using one-way Kruskal-Wallis test at each individual time point with no correction for the 
four pre-selected comparisons. Error bars represent SD. N=5-9 animals per group. CTRL = littermate c14/c14 animals. 
For A and B, *P<0.05, **P<0.01 and ***P<0.001 using two-way ANOVA with Tukey´s post hoc test. Error bars 
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Comparison of AAV9 and AAV2retro-based vectors in CNS transduction efficacy. 
In the previous parts of this Chapter, we described a gene therapy approach to overexpress 
a potential modifier in MNs using a viral vector targeting MNs. For gene therapy to succeed, it is 
important that the viral vector delivers the transgene efficiently to the majority of the intended 
target cells. Although AAV9 is one of the most commonly used AAV serotypes for gene delivery 
into CNS222-225 and MNs in particular226-228, it has its disadvantages, including low neuronal 
transduction within the mouse brain and targeting of astrocytes in mouse CNS. AAV2retro was 
originally developed for retrograde tracing to study neuronal connectivity in CNS229, however, its 
efficacy in MN transduction upon ICV injection in neonatal mice was not sufficiently studied. 
Therefore, we decided to evaluate the efficacy of gene transduction using a GFP-expressing 
construct packaged into AAV9 and AAV2-retro capsids. 
Neonatal mice were injected with the same dose of either AAV9 or AAV2-retro GFP virus 
via ICV route. After 4 weeks, the profile of GFP expression was analyzed in both groups. 
Gross visual examination of the CNS from injected mice under fluorescent light showed 
bright GFP signal from brain, spinal cord, and dorsal root ganglia in the AAV2-retro group (Fig. 
3-5). In AAV9-injected animals, GFP fluorescence was slightly above the background level (Fig. 
3-5). Histological analysis of longitudinal spinal cord sections at cervical and lumbar levels 
revealed GFP-positivity predominantly in MNs for both AAV9 and AAV2-retro groups (Fig. 3-
6A). In the AAV2-retro group, prominent GFP signal was observed in nerve fibers of the dorsal 
tracts, and no GFP-positive astroglial cells were seen. In the AAV9 group, occasional astrocytes 
were positive for GFP. Quantitative comparison of MN transduction efficacy showed a similar 
percentage of GFP-positive MNs for both AAV capsids within each anatomical region: over 70% 
of cervical and over 50% of lumbar MNs expressed GFP (Fig. 3-6B). Analysis of brain sections 
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from AAV2-retro-injected animals revealed widespread GFP positivity of neuronal cells from 
various anatomic regions, including thalamus, hippocampus, and deep cortical layers (Fig. 3-
7A,B). In the AAV9 group, GFP positivity was also detected in thalamus, hippocampus and 
limited cortical regions, however, the majority of GFP-positive cells were astrocytes (Fig. 3-7A,B). 
These data show that AAV2-retro and AAV9 transduce a comparable proportion of MNs 
at both cervical and lumbar levels, however, AAV2-retro more efficiently transduces cortical 
neurons. These data suggest that compared to AAV9, AAV2-retro is a preferred vector for CNS-
























Representative images of dissected CNS from mice injected with AAV2-retro (left) or AAV9 (middle) viruses 























A. Representative longitudinal sections of cervical spinal cord from animals injected with AAV2retro (left panels) or 
AAV9 (right panels) viruses expressing GFP under CAG promotor. 
B. Percentage of GFP-positive MNs in cervical and lumbar spinal cord sections from animals injected with AAV2retro 
















































A. Representative coronal sections of cerebral hemispheres from animals injected with AAV2retro (left) or AAV9 
(right) viruses expressing GFP under CAG promotor. 
B. High-power images of layer V cells of primary motor cortex from these animals show widespread neuronal 





Targeting neuroinflammation in FUS ALS  
There is extensive evidence supporting the critical role of neuroinflammation in the 
pathogenesis of ALS. Reactive microglia and astrocytes in the spinal cords from patients with ALS 
were first reported in late 1980s230. Around the same time, T-cell infiltration of ventral horns and 
degenerating corticospinal tracts in the majority of ALS patients was observed231,232. There is also 
evidence of immunoglobulin233,234 and complement234 deposition in ALS patients’ CNS. These 
studies were conducted using post mortem tissues from patients with end-stage disease so likely 
do not reflect early neuroinflammatory changes, which are very challenging to study in humans. 
More recently, PET imaging with a labeled compound specific to activated microglia revealed 
widespread cerebral neuroinflammation correlating with the burden of clinically-observed upper 
motor neuron signs235. 
Recent genetic studies revealed mutations in several genes involved in immune signaling 
to be causative in ALS. For example, ALS-associated mutations in OPTN236 prevent it from 
inhibiting NF-κβ activation, one of the normal functions of this protein237. Loss-of-function 
mutations in TBK1 linked to ALS238 were shown to disrupt its interaction with OPTN239 leading 
to the impairment of its function in autophagy and NF-κβ inhibition. TBK1 is also involved in 
numerous innate immune signaling pathways, including NF-κβ activation240-242, toll-like receptors 
(TLR2 and TLR4) signaling243, IRF3-dependent antiviral gene expression242,244 and others. 
Another gene associated with ALS and FTD, CYLD245, is another negative regulator of NF-κβ246 
supporting an important role of this signaling pathway in the disease pathogenesis. 
C9orf72 protein has also been implicated in immune system function. Homozygous 
C9orf72 knockout mice develop immune dysregulation characterized by leukocytes expansion and 
increased autoantibody production, resulting in a phenotype resembling systemic lupus 
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erythematosus59. Macrophages and microglia from C9orf72 null mice have enhanced cytokine 
production in response to inflammatory stimuli that might contribute to the age-related 
neuroinflammation observed in these animals247. Myeloid cells derived from C9orf72 deficient 
mice have increased interferon type I production through a STING-dependent mechanism248. 
These studies suggest C9orf72 has an important role in preventing excessive immune activation 
and suppressing autoimmunity. However, C9orf72 null mice do not develop any motor deficits, 
suggesting that C9orf72 is unlikely to cause ALS through a loss-of-function mechanism59. 
Nevertheless, C9orf72 deficiency and resulting immune system hyperactivation might exacerbate 
the pathology caused by C9orf72-HRE through a gain-of-function mechanism249,250. Consistent 
with this hypothesis, recent studies have shown that C9orf72 deficiency exacerbates DPR toxicity 
in MNs in vitro251 and cause earlier motor deficits in transgenic C9orf72-HRE-overexpressing 
mice252. 
Interestingly, TDP-43 overexpression in glial cells was shown to activate NF-κβ signaling 
and result in a higher production of proinflammatory cytokines in response to LPS253. Similarly, 
FUS was shown to directly interact with p65 subunit of NF-κβ complex to enhance its activation 
in response to physiological stimuli81. Moreover, the antiviral immune response caused by dsRNA 
stimulation triggered pathological FUS aggregation in various cells254 linking innate immune 
signaling directly to FUS toxicity. 
Due to the difficulties studying early events leading to neuroinflammation and 
neurodegeneration in patients with ALS, most of these studies use animal models. Consistent with 
the important role of immune mechanism in ALS, many of those studies report early alterations in 
microglial or astroglial cells, often preceding disease onset in the animals255-257. Moreover, studies 
of TLR4 as a critical component of innate immune signaling in SOD1G93A mouse model of ALS 
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showed that TLR4 knockout significantly ameliorates the disease phenotype and extends lifespan 
of transgenic animals258. Administration of a TLR4 antagonist was also reported to decrease 
neuroinflammation and rescue morphological alterations of motor neurons in a wobbler mouse of 
spontaneous motor neuron degeneration259. Moreover, some of the studies showed that disease-
associated astrocytes260 and microglia261 can directly cause motor neuron death. Interestingly, one 
of these studies reported an early secretion of the anti-inflammatory cytokine IL-10 by microglia 
in pre-symptomatic SOD1G93A mice256. Administration of anti-IL-10R antibody resulted in 
increased microglial activation and earlier disease onset. Conversely, upregulation of IL-10 in 
microglial cells via viral delivery delayed the onset of the symptoms, suggesting a protective role 
of microglia early in the course of the disease. There is increasing evidence that neuroinflammation 
is not always damaging but could also be protective and limit neurological injury262-265. This 
suggests that neuroinflammation could play different functional roles at different stages of the 
disease. Consistent with this hypothesis, another study reported that treating SOD1G93A mice with 
minocycline, an antimicrobial drug with anti-inflammatory properties, before the onset of 
symptoms confers neuroprotection, however, the same treatment after the disease onset 
exaggerated neuroinflammation257. 
Our data described in Chapter 1 showed that micro- and astrogliosis were one of the earliest 
events preceding MN loss in FUS knock-in animals. Moreover, microgliosis also occurred prior 
to MN loss in animals with conditional expression of mutant FUS selectively in MNs. This 
suggests that microgliosis and neuroinflammation play an important pathogenic role in the disease 
in a manner that does not depend on the expression of mutant FUS in immune cells.  
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Chronic LPS administration in conditional compound heterozygous model 
In order to test this hypothesis, we treated MN-P517L/Δ14 and control animals with either 
low-dose LPS (0.5 mg/kg weekly via intraperitoneal injection) or vehicle starting at postnatal day 
40. This protocol was well-tolerated and none of the experimental animals developed any adverse 
effects. Immunostaining analysis of the spinal cord sections for a microglial marker Iba1 showed 
that this treatment induced sustained microgliosis in both MN-P517L/Δ14 and control animals 
(Fig. 3-8A). Interestingly, LPS-treated MN-P517L/Δ14 animals had a higher density of microglial 
cells in lumbar spinal cord sections starting at 4 months of age in comparison to LPS-treated 
controls which might reflect differences in response to LPS dependent on mutant (P517L) FUS 
expression. 
Analysis of MN numbers in L4-L5 lumbar segments from the spinal cords of these animals 
revealed that vehicle-treated MN-P517L/Δ14 animals had ~15% and ~18% decrease in MN 
numbers at 4 and 6 months of age respectively, consistent with prior observations of this model 
(Fig. 3-8B). Unexpectedly, LPS-treated MN-P517L/Δ14 animals did not develop MN loss at these 
time points. 
One possible explanation is that early LPS treatment prior to the onset of microgliosis in 
this model prevented the formation of disease-associated microglia by inducing a different pro-
inflammatory state of microglia in response to LPS. An alternative, although not exclusive 
hypothesis is that LPS induced a specific cellular response through TLR4 on MNs258 that directly 
affected their survival. Immunofluorescent analysis of spinal cord segments stained for NF-κβ, a 
downstream mediator of TLR signaling266, showed widespread nuclear localization of NF-κβ in 
most neuronal cells including MNs (Fig. 3-9), supporting the second hypothesis, although not 
ruling out the first. Further studies, including investigating the role of innate immune signaling 
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through TLR4 in MNs and immune cells, profiling microglia from MN-P517L/Δ14 animals, and 
identifying CNS-infiltrating lymphocytes, are planned to elucidate the involvement of immune 














A. Density of Iba1-positive microglial cells at lumbar levels 4 and 5 in vehicle-treated FUS WT-expressing CTRL 
(green), LPS-treated FUS WT-expressing CTRL (orange), vehicle-treated FUS mutant (MN-P517L/Δ14) (red), and 
LPS-treated FUS mutant (MN-P517L/Δ14) (purple) animals. 
B. Numbers of ChAT positive motor neurons at lumbar levels 4 and 5 in vehicle-treated FUS WT-expressing CTRL 
(green), LPS-treated FUS WT-expressing CTRL (orange), vehicle-treated FUS mutant (MN-P517L/Δ14) (red), and 
LPS-treated FUS mutant (MN-P517L/Δ14) (purple) animals normalized to the vehicle-treated FUS WT-expressing 
CTRL. 
For A and B, *P<0.05, **P<0.01 and ***P<0.001 using two-way ANOVA with Tukey´s post hoc test. Error bars 





























Representative immunostaining of spinal cord sections from FUS mutant (MN-P517L/Δ14) and FUS WT-expressing 
CTRL animals treated with LPS or vehicle from 5 weeks until 6 months of age. ChAT-positive MNs are shown in 





Experiments described in Chapter 3 aimed to investigate the role of potential modifiers of 
FUS toxicity and molecular pathways that could be targeted therapeutically. 
Firstly, we explored the role of hnRNP U in MNs, its interaction with FUS and its 
overexpression in MNs in vivo in the context of mutant FUS. We found that hnRNP U co-
immunoprecipitates with FUS with or without ALS-associated mutation. Although previous work 
in the laboratory suggested that hnRNP U interacts with mutant FUS to a higher extent than WT 
FUS, those results were obtain using a targeted transgenic mouse model in which a human FUS 
(hFUS) cDNA is expressed from the MAPT locus. That model shows a much higher expression of 
mutant hFUS compared to WT hFUS, possibly due to the lack of endogenous regulatory elements 
in the mRNA transcripts produced from the transgenic cDNA sequence. In this context, protein 
levels are largely dependent on protein stability and mutant FUS has been shown to be more stable 
and have a slower turnover than WT FUS. In the knock-in mouse model of ALS FUS, we 
introduced the mutations directly into the mouse genome, preserving all endogenous regulatory 
elements. This results in comparable levels of mutant or WT FUS protein produced from each 
allele, enabling quantitative comparison of interactors specific to either of these FUS protein 
species. Replicating previous co-IP and mass spectrometry experiments in this new, more disease-
relevant knock-in mouse model would help to identify differential protein interactors of WT or 
mutant FUS in a more technically reliable way. 
When analyzing the consequences of MN-specific hnRNP U elimination, we discovered 
that some subpopulations are more susceptible or resistant to neurodegeneration induced by the 
loss of this essential protein. Similar to the selective vulnerability observed in ALS, α-MNs but 
not γ-MNs are predominantly lost. However, when analyzing muscle denervation profile in those 
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animals, we found that flexor muscles were predominantly affected while extensor muscles were 
largely spared. Muscles innervated from cranial nuclei were affected to a different degree, 
moreover, some muscles innervated from the same nucleus (III, oculomotor) showed a differential 
resistance to denervation with some muscles (mm. recti superior et inferior) being affected and 
others (m. rectus medialis, m. obliquus inferior, and m. levator palpebrae superioris) completely 
spared. In addition, preganglionic ChAT-positive neurons of both sympathetic and 
parasympathetic parts of autonomous nervous system showed subtotal loss. Although such 
differential vulnerability profile does not precisely match the one observed in ALS, it nevertheless 
represents an interesting phenomenon of differential susceptibility of postmitotic MNs with 
different functional identity to a pathologic loss of an essential, ubiquitously expressed protein. 
Considering that RBPs are orchestrating numerous steps of RNA metabolism and regulate gene 
expression and alternative splicing responsible for establishing the identity of a cell, their 
involvement through the pathological sequestration by mutant FUS, TDP-43, or C9orf72-HRE 
RNA might at least partially explain the differential vulnerability of MNs observed in ALS. 
Considering the extensive evidence of hnRNP U involvement in ALS-FUS, we sought to 
evaluate the efficacy of AAV9-mediated gene therapy by overexpressing hnRNP U in MNs. 
Perhaps not surprisingly, this treatment failed to provide any therapeutic benefit to the 
experimental animals (MN-P517L/Δ14). Our data and studies from other groups suggest the 
involvement of numerous RBPs in the pathological process, and although many of these RBPs 
have a certain degree of functional redundancy, they have their unique and cooperative functions 
in concert with other RBPs. This suggests that, as we observed in case with hnRNP U, an 
overexpression of a single RBP is unlikely to overcome the more widespread deficiency of RBP 
function and fully rescue MN degeneration in ALS-FUS. 
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Secondly, we focused on a different gene therapy candidate, UPF1, a critical component 
of NMD pathway that was previously shown to be protective against toxicity associated with 
overexpression of FUS, TDP-43, and C9orf72-HRE in various cellular and animal models. 
Consistent with those observations, we showed that a single perinatal injection of AAV9-UPF1 
completely rescues MN loss, denervation and associated gliosis in FUS mutant (MN-P517L/Δ14) 
animals. These data, acquired from the most disease-relevant model of ALS-FUS available to date, 
strongly supports the use of UPF1 gene therapy to treat ALS-FUS and other forms of ALS, 
considering their similarities in terms of involvement of various RBPs in the pathological process 
and associated alterations in mRNA metabolism. Although the hypothesized mechanism of action 
of UPF1 activity is through upregulation of NMD and facilitated clearance of potential toxic 
transcripts with PTCs, the exact mechanism is not yet established. Also, conflicting reports 
regarding the role of NMD in ALS warrant further investigation. 
Lastly, we aimed to investigate the effect of chronic LPS-induces neuroinflammation on 
the disease progression in FUS knock-in animals. Using weekly intraperitoneal administration of 
low-dose LPS, we successfully, induced sustained microgliosis and widespread NF-κβ activation 
across multiple cell types in spinal cords of treated animals. Interestingly, FUS mutant (MN-
P517L/Δ14) animals had a higher density of microglial cells in their spinal cord in comparison to 
control animals that may reflect the differences in response to LPS between FUS WT- and FUS 
P517L/WT-expressing microglia. Unexpectedly, this treatment also resulted in rescue of MN loss 
phenotype in MN-P517L/Δ14) mice. Although the exact mechanism of this phenomenon is yet to 





The work presented in this dissertation aimed to investigate the mechanism of toxicity of 
FUS protein with ALS-associated mutations and to target it therapeutically. To do that, we 
generated a series of genetic knock-in mice carrying ALS associated mutations in FUS gene, 
P517L (corresponding to human P525L mutation) and conditional Exon14 allele (corresponding 
to human exon 14 splice acceptor site mutation G466Vfs14X) generated by flanking exon 14 of 
FUS with loxP sites, allowing for conditional Cre-dependent mutant gene expression. Animals 
heterozygous for either P517L or Δ14 allele develop age-related MN degeneration after 1 year of 
age with selective vulnerability profile characteristic of ALS, suggesting a high disease relevance 
of these alleles. 
In combination with a FUS knockout allele, we performed a series of genetic crosses with 
these animals and showed that both P517L and Δ14 retain incomplete function as either allele is 
only partially capable of rescuing the knockout perinatal lethality phenotype. However, both 
alleles exhibit developmental toxicity that is dose dependent as both P517L/P517L and P517l/Δ14 
genotypes show much earlier mortality than P517L/KO mice. The P517L allele also appeared to 
be more toxic than Δ14 which is also supported by decreased long-term survival of P517L/WT 
animals in comparison to Δ14/WT. 
We also showed that both species of mutant FUS mislocalize to the cytoplasm, with Δ14 
protein showing a higher degree of cytoplasmic mislocalization in comparison to the P517L 
protein. Interestingly, most commercial antibodies that we tested did not stain cytoplasmic FUS in 
MNs in spinal cord sections, though mutation-specific antibodies clearly detecting the 
corresponding FUS protein in the cytoplasm. Some commercial antibodies, especially the ones 
raised against the extreme N-terminus of FUS, retained that differential affinity towards WT but 
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not mutant FUS even on WB under denaturing conditions. These data suggest that mutant FUS 
protein might have different PTMs within its N-terminus in comparison to WT protein and/or an 
entirely different spatial conformation masking the epitopes of these antibodies. Both these 
changes can affect FUS interactions with other proteins and RNA species and affect its toxicity. 
Using serial biochemical fractionations in buffers with increasing ionic strength and 
detergent content, we show that P517L protein has a higher propensity to partition into sarkosyl-
insoluble fraction in a dose-dependent manner along with other FUS-interacting RBPs, including 
TDP-43, hnRNP A1, hnRNP U, UPF1, and others. FUS Δ14 allele shows a similar trend of 
increased insolubility and other RBPs involvement, albeit to a lesser extent, possibly due to the 
lack of the most C-terminal RGG domain required for phase separation. This suggests that mutant 
FUS protein’s ability to phase separate and interact with other RBPs is a primary determinant of 
its toxicity rather than cytoplasmic mislocalization alone. Our data show that Δ14 allele is less 
toxic than P517L despite a higher degree of cytoplasmic mislocalization. This supports the 
hypothesis that ALS-associated FUS toxicity is mediated through FUS interactions with other 
proteins and/or RNA species. 
Using the conditional Δ14 allele we show that the observed MN loss phenotype is a cell-
autonomous process dependent on mutant FUS expression only in MNs regardless of mutant FUS 
expression in other cells. Although non-cell autonomous contributions from non-MN cells might 
contribute to MN degeneration, these effects appear to be independent of mutant FUS expression 
in those cells. Although mutant FUS expression in immune cells can alter their functional state 
through a combination of gain- and loss-of-function mechanisms, the contribution of these effects 
to MN pathology is not clear. Our preliminary data suggest that mutant FUS might enhance type I 
interferon production by mouse bone marrow-derived macrophages in response to pro-
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inflammatory stimuli. This supports a hypothesis that mutant FUS protein in MNs is necessary for 
MN degeneration but mutant FUS expression in immune cells creates a pro-inflammatory 
environment further promoting MN pathology. However, to what extent these mutant FUS-
dependent changes in immune cell function contribute to MN loss in a complex in vivo system 
requires additional studies. The data from our mouse models argue that mutant FUS expression in 
non-MN cells is not required for initiation or progression of MN loss and that contribution of 
mutant FUS-dependent non-MN-autonomous effects to MN loss are rather minor to be detected. 
Increasing the dose of Δ14 protein in MNs resulted in an accelerated MN loss in comparison to 
heterozygous animals. Using a more toxic P517L allele to generate MN-P517L/Δ14 animals 
exacerbated the phenotype; these animals developed MN loss after 3 months of age while 
preserving the selective vulnerability profile characteristic of ALS. This argues for the disease 
relevance of the MN-P517L/Δ14 model that has a more favorable time to onset of a motor 
phenotype in comparison to heterozygous animals, making it a more tractable system in which to 
study disease mechanism and evaluate the efficacy of candidate therapeutics. Interestingly, in all 
the genotypes we generated and characterized, MN loss does not progress beyond ~20% and MN-
P517L/Δ14 animals show slow re-innervation of the affected muscles after reaching that “plateau” 
of MN loss. This suggests nearly complete loss of a vulnerable subpopulation of MNs in mice, 
leaving resistant MNs to mediate functional recovery. Future studies to identify the molecular 
determinants of the selective MN vulnerability observed in this model will provide critical insight 
to disease mechanisms and suggest therapeutic strategies to protect vulnerable MNs in ALS. 
Consistent with dose-dependency of mutant FUS toxicity, we showed that decreasing the 
levels of FUS protein in MN-P517L/Δ14 using a non-allele-specific ASO significantly delays the 
onset of the disease in this model. Moreover, FUS knockdown also decreases the levels of 
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associated RBPs in sarkosyl-insoluble fractions, highlighting the dependence of this process on 
FUS. The involvement of multiple RBPs, including TDP-43, hnRNP H, hnRNP A1, and others in 
the pathological process shows remarkable similarity to the previously reported, widespread 
insolubility of these RBPs in the majority of C9orf72-positive cases and up to a third of sporadic 
cases of ALS. This suggests a common underlying mechanism and the possibility of therapeutic 
targeting of critical protein-protein interactions required for the formation of these specific 
insoluble condensates. The downstream consequences of this widespread RBPs insolubility on 
RNA processing and the exact mechanism of how RNA metabolism dysregulation causes MN 
death remain to be elucidated. 
Consistent with our preclinical findings with ION363, the data from the first treated patient 
with a FUS P525L mutation show a dramatic reduction of FUS protein to nearly undetectable 
levels and reduction of sarkosyl-insoluble RBPs in comparison to a non-treated patient with the 
same FUS mutation. Moreover, spinal cord and motor cortex sections from the ION363-treated 
patient showed a remarkable reduction in the burden of FUS aggregates, suggesting either 
prevention of their formation or their elimination through proteostatic mechanisms as a 
consequence of reduced levels of FUS protein. Importantly, none of the 12 patients who have 
received ION363 treatment at the time of writing this dissertation, reported any significant side 
effects. Although it is impossible to reach a conclusion about the clinical efficacy of this FUS-
lowering therapeutic, our preliminary data demonstrating consistent reduction of NF-L and pNF-
H levels - two diagnostic and prognostic, albeit non-specific disease biomarkers in ALS - in both 
CSF and blood samples from several ALS-FUS patients treated with ION363 suggest that the 
experimental antisense therapeutic may be neuroprotective, and provide encouraging evidence that 
the ongoing clinical trial may demonstrate clinical benefit in this population. 
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Lastly, we show the conditional compound heterozygous (MN-P517L/Δ14) mouse that we 
generated and characterized is a highly disease-relevant animal model of ALS-FUS in which to 
conduct mechanistic studies and to identify and evaluate potential disease modifiers. Although 
viral overexpression of one of the interactors of FUS, hnRNP U, did not rescue MN loss 
phenotype, a related set of experiments involving MN-specific hnRNP U knockout showed a 
unique pattern of selective vulnerability of MN loss upon elimination of a critical ubiquitously 
expressed protein. This phenomenon of differential survival dependence of MNs on various RBPs 
expression might underlie selective vulnerability observed in ALS, considering widespread 
involvement of RBPs in the disease pathogenesis. We also showed a complete phenotypic rescue 
by UPF1, one of the two gene therapy candidates we evaluated. As a major activator of NMD, 
UPF1 might act downstream of RBP insolubility and counteract RNA toxicity by promoting 
elimination of potentially toxic misspliced transcripts. Additionally, we demonstrated an 
unexpected prevention of MN loss in this model by chronic low-dose LPS administration, which 
suggests the involvement of innate immune signaling in the pathogenesis of ALS-FUS. Although 
additional studies are required to elucidate the exact molecular mechanisms that underlie these 
observations, these findings could lead to the development of additional therapeutics targeting 
various pathological pathways in ALS-FUS that could alone or in combination with FUS-lowering 
treatment provide clinical benefit to patients and families with this aggressive form of ALS, and 
possibly to the larger community of ALS patients.  
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Materials and methods 
Human subjects, tissue samples and ION363 drug 
Administration of the experimental antisense oligonucleotide ION363 to individual 
patients was approved by FDA through the Expanded Access program. All experiments involving 
human subjects were approved by the Institutional Review Board at Columbia University Irving 
Medical Center. 
ION363 (Jacifusen) drug 
ION363 is a sodium salt of an oligonucleotide with a chemically modified backbone to 
improve its stability267. The sequence of ION363 corresponds to 5’-
GCAATGTCACCTTTCATACC-3' sequence within the 6th intron of FUS gene. 
ION363 was manufactured by ChemGenes Corporation according to GMP standards. For 
the animal experiments, drug powder was reconstituted in sterile PBS to a total concentration of 4 
mg/mL. For the administration to the patient, ION363 was reconstituted in a USP compendial 
grade artificial CSF to a total concentration of 11 mg/mL. The appropriate drug volume for 20 mg, 
40 mg, and 60 mg doses was subsequently sterilized through a 0.2-µm filter into a sterile pyrogen-
free syringe. 
Mouse lines and procedures 
All experiments involving life animals were approved by the Institutional Animal Care and 
Use Committee at Columbia University Irving Medical Center. C57Bl/6J (#000664), ChAT-Cre153 
(#006410), ChAT-CreΔneo (#031661), Protamine-Cre268 (#003328), and Pgk1-flpo269 (#011065) 
mouse lines were obtained from Jackson Laboratory (JAX, Bar Harbor, ME). 
Mutant FUS knock-in and FUSKO (EUCOMM allele FUStm1d)96 mice were previously 
generated in the laboratory140. 
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UPF2Flox mouse line was previously established221. hnRNPUFlox mouse line was received 
from Maniatis laboratory177. UPF2KO and hnRNPUKO mice were generated by first crossing 
UPF2Flox or hnRNPUFlox alleles to Protamine-Cre line and subsequently crossing the 
corresponding Flox/WT; Protamine-Cre positive males to C57Bl/6J females. 
All strains were backcrossed to C57Bl/6J background for at least 5 generations. 
All primer sequences used for genotyping are listed in Table 1. 
Motor function evaluation was performed using grip strength test (Bioseb, BIO-GS3). 
For intracerebroventricular injections, newborn animals were first anesthetized on ice and 
then 20 μg of ION363, NTC oligonucleotide, or 5*1010 vg of AAV vector in a total volume of 5 
μl were injected into the right lateral ventricle (2 mm frontal and 1 mm lateral to the bregma) using 
Hamilton Neuros syringe. After the injection, animals were placed on a heating pad and monitored 
until recovery. 
To induce chronic neuroinflammation, mice were treated with 0.5 mg/kg LPS dissolved in 
PBS once a week via intraperitoneal injections. 
To collect fixed tissue samples, the animals were transcardially perfused with PBS-heparin 
solution followed by 4% paraformaldehyde; brain, spinal cord, and muscles (diaphragm, tibialis 
anterior, and soleus) were dissected. 
PCR and RT-PCR 
RNA from brain or spinal cord samples was isolated with Trizol reagent (Invitrogen), its 
concentration was measured using NanoDrop 2000 (Thermo Scientific), and cDNA was generated 
with SuperScript IV reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. 
GoTaq G2 Hot Start Master Mix (Promega) and PowerUp SYBR Green Master Mix (Thermo 
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Scientific) were used to set up PCR or qPCR reactions respectively. All primers used in this study 
are listed in Table 1. 
Immunofluorescence 
Spinal cord samples were sectioned at 70 µm thickness on Leica VT 1000S vibratome. 
Tibialis anterior and soleus muscles were sections at 35 µm thickness on Leica CM 3050S cryostat. 
Diaphragms were stained as whole mount. 
Tissue sections were incubated in primary antibodies (Table 2) diluted in 5% NDS in Tris-
buffered saline with 0.5% Triton X-100 (TBS-T) overnight at +40C. The sections were then 
washed in TBS-T three times and incubated with the corresponding secondary antibodies (Table 
2) for 1 h. After three washes in TBS-T, the sections were mounted in aqueous medium 
(Flouromount G, Southern Biotech, Birmingham, AL, USA) and imaged using Leica SP8 confocal 
microscope. Images were analyzed using LAS X and ImageJ software packages. 
Western blotting 
Tissue lysates were mixed with 4x SDS sample buffer, incubated at 1000C for 5 min, and 
run on Novex WedgeWell Tris-Glycine gels (4-20%, 8-16% or 10-20%; Thermo Fisher) and 
transferred onto nitrocellulose membranes (Thermo Fisher) using mini-blot modules (Thermo 
Fisher). The membranes were then blocked in Pierce Protein-Free T20 (TBS) Blocking Buffer 
(Thermo Fisher) and incubated with the corresponding primary antibodies (Table 2) overnight at 
+40C. Then, the membranes were washed in TBS with 0.1% Tween-20 three times and incubated 
with HRP-conjugated secondary antibodies (Table 2) for 1 h. After three washes in TBS-Tween-
20, the membranes were treated with SuperSignal West Pico or SuperSignal West Femto (Thermo 




For immunoprecipitation, Pierce Protein A/G Magnetic Beads were equilibrated in the 
Wash Buffer (0.05% Tween-20 in TBS) and then incubated with the corresponding primary 
antibody or isogenic control (Table 2) with end-over-end rotation at +4°C overnight. Beads were 
washed three times with the Wash Buffer and incubated with tissue lysates with end-over-end 
rotation at +4°C for 3-5 hours. After three washes with the Wash Buffer, protein 
immunocomplexes were eluted from the beads with the Elution Buffer (0.1M glycine, pH 2.0) and 
neutralized with the Neutralization Buffer (1M Tris; pH 9). 
Nucleo-cytoplasmic fractionation 
This protocol was adapted from Shiihashi et al.270 Frozen tissue samples were weighed and 
homogenized in 10 μl per 1 mg of tissue of cytoplasmic buffer (10 mM Hepes, 10 mM NaCl, 1mM 
KH2PO4, 5 mM NaHCO3, 5 mM EDTA, 1 mM CaCl2, 0.5 mM MgCl2). After incubating the 
homogenized tissue on ice for 10 min, 0.5 μl /mg of 2.5 M sucrose was added and centrifuged at 
6,300 x g for 10 min. The supernatant was collected as the cytoplasmic fraction and the pellet was 
washed three times with the nuclear buffer (10 mM Tris pH 7.4, 300 mM Sucrose, 1 mM EDTA, 
0.1% Nonidet-40), homogenized and centrifuged at 1,000g for 5 min. The pellet was resuspended 
in 5 μl per 1 mg of tissue of IP buffer containing 2% SDS as the nuclear fraction. 
Subcellular fractionation with sarkosyl 
This protocol was adapted from Conlon et al.107 Tissue samples were weighed and for every mg 
of tissue, 18 μl of ice-cold soluble buffer (0.1 M MES pH 7, 1 mM EDTA, 0.5 mM MgSO4, 1 M 
sucrose) containing 50 mM N-ethylmaleimide (NEM), 1 mM NaF, 1 mM Na3VO4, 1 mM PMSF 
and Halt protease and phosphatase inhibitor cocktail (Thermo Fisher) was added. Samples were 
homogenized by several passages through needles with decreasing diameter (20-, 23-, and finally 
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271/2-gauge needles). An equivalent volume of the homogenate (700 μl) was collected and 
centrifuged at 50,000g for 20 min at 40C. The supernatant was collected as a soluble fraction. The 
pellet was resuspended in 700 μl of RAB buffer (100 mM MES pH 6.8, 10% sucrose, 2 mM EGTA, 
0.5 mM MgSO4, 500 mM NaCl. 1 mM MgCl2, 10 mM NaH2PO4, 20 mM Na, 1 mM PMSF, 50 
mM NEM) containing 1% of N-lauroylsarcosine (Sarkosyl), and Halt protease and phosphatase 
inhibitor cocktail (Thermo Fisher), vortexed for 1 min at RT and incubated at 40C overnight with 
end-over-end rotation. The samples were then centrifuged at 200,000g for 30 min at 120C, and the 
supernatant was collected as the sarkosyl-soluble fraction. The pellet was resuspended in 700 μl 
of RAB buffer and passed 3-5 times through a 271/2 gauge-needle to fully disperse the pellet, 
creating the sarkosyl insoluble fraction. 
Immunohistochemistry 
5 μm tissue sections were deparaffinized in xylene and rehydrated in ethanol solutions with 
decreasing concentrations. Antigen retrieval was performed by autoclaving the slides in Tris-
EDTA buffer (10 mM Tris ph 9, 1 mM EDTA, 0.05% Tween20) for 10 minutes. The slides were 
then washed in TBS and incubated with primary antibodies (Table 2) in TBS solution with 0.01% 
Triton X-100 and 5% normal goat serum overnight at +40C. On the next day, the slides were 
washed three times in TBS and incubated with HRP-conjugated secondary antibodies (Table 2). 
After three washes in TBS, the slides were developed with DAB Substrate Kit (Thermo Fisher) 
for 10 min and counterstained with Mayer’s hematoxylin for 2 min. The slides were then 
immediately rinsed in tap water for 5 min, dehydrated in ethanol solutions with increasing 





Statistical analysis was performed using GraphPad Prism 9.0.2 software package. 
 
Table 1. Oligonucleotides used in the study. 
Name Sequence Use Notes 
KIN F TTGTAAACTTACAATTCAGGATCGCTCATGG Genotyping 315 bp for FUS KIN 
and 245 bp for WT KIN R CAATTCTTGCTGTGCAAGACAATTTCTGG Genotyping 
Ex14 F GGAGCAGAGCTGGAACTGAGAGCTC Genotyping 201 bp for c14, 295 bp 
for Δ14, and 140 bp 
for WT alleles 
Ex14 R1 GCCACGTCGATCATCTCCATAGTTTC Genotyping 
Ex14 R2 ATCCATGAGCGATCCTGAATTGTAAGTTTAC Genotyping 
FUS KO F1 TGAAGATCACCGTGAAACACTGGGCTAGG Genotyping 298 bp for FUS KO 
and 192 bp for WT 
alleles 
FUS KO F2 GTCTCATAAGCCAGGGAGTACCTTCAGTGG Genotyping 
FUS KO R TTTGGCTCCCAAGTTCTCACAAAAACATAATAGG Genotyping 
hnRNPDL 
Ex8 F 
GGGGCGGCAATCACCAGAACA PCR 200 bp for inclusion 
and 95 bp for 





CCACCCTTCTCATGTTCAGCC PCR 297 bp for inclusion 
and 128 bp for 





Name/Target Source Catalog # Species Use Dilution 
Primary antibodies 
Synaptophysin Invitrogen 18-0130 Rabbit IF 1:1,000 
Neurofilament, pNF-H Millipore-Sigma MAB1592 Mouse IF 1:200 
ChAT Millipore-Sigma AB144P Goat IF 1:250 
Iba1 Wako Chemicals 019-19741 Rabbit IF 1:5,000 
GFAP Dako Z0334 Rabbit IF 1:2,000 
FUS-PTech[52-400] Proteintech 11570-1-AP Rabbit 
WB 1:5,000 
IF 1:1,000 
FUS-Abcam[1-50] Abcam ab84078 Rabbit 
WB 1:5,000 
IF 1:250 
FUS-SC["C-term"] Santa Cruz 4H11 sc-47711 Mouse 
WB 1:500 
IF 1:250 










3 µg per 
reaction 
FUS-P517L(P525L) 





















TNPO1 Novus biologicals 
NB600-
1397 




#12040 Rabbit WB 1:1,000 
Caprin1 Proteintech 15112-1-AP Rabbit WB 1:1,000 
TDP-43 Proteintech 10782–2-AP Rabbit WB 1:4,000 
hnRNP U Bethyl A300-689A Rabbit WB 1:1,000 
hnRNP H Bethyl A300-511A Rabbit WB 1:7,000 
hnRNP A1 Millipore-Sigma 05-1521 Mouse WB 1:1,000 
hnRNP K Invitrogen MA1-087 Mouse WB 1:1,000 
NF-kβ Abcam Ab7970 Rabbit IF 1:1,000 
anti-ASO154 Ionis Pharmaceuticals N/A Rabbit 
IF 1:10,000 
IHC 1:10,000 
GAPDH Millipore-Sigma MAB374 Mouse WB 1:10,000 
H3 Abcam ab1791 Rabbit WB 1:10,000 
DYKDDDDK Tag Antibody Cell Signaling #2368 Rabbit IP 
3 µg per 
reaction 
   
Secondary antibodies and conjugates 
Tetramethylrhodamine α-Bungarotoxin Invitrogen T1175 N/A IF 1:1,000 
α-Bungarotoxin, Alexa Fluor488 
conjugate 
Invitrogen B13422 N/A IF 1:1,000 
   
Donkey anti-Goat IgG, Alexa Fluor 555 Invitrogen A-21432 Donkey IF 1:1,000 
Donkey anti-Goat IgG, Alexa Fluor 488 Invitrogen A-11055 Donkey IF 1:1,000 
Donkey anti-Rabbit IgG, Alexa Fluor 
Plus 647 
Invitrogen A32795 Donkey IF 1:1,000 
Donkey anti-Mouse IgG, Alexa Fluor 
Plus 488 
Invitrogen A32766 Donkey IF 1:1,000 
Donkey anti-Mouse IgG, Alexa Fluor 
Plus 647 
Invitrogen A32787 Donkey IF 1:1,000 
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706-175-148 Donkey IF 1:1,000 




706-165-148 Donkey IF 1:1,000 
DyLight™ 405 AffiniPure Donkey Anti-
Mouse IgG (H+L) 
Jackson 
ImmunoResearch 
715-475-150 Donkey IF 1:1,000 
   
Goat anti-Rabbit IgG (H+L) Secondary 
Antibody, HRP 
Invitrogen 31460 Goat WB 1:10,000 
Goat anti-Mouse IgG (H+L) Secondary 
Antibody, HRP 
Invitrogen 31430 Goat WB 1:5,000 
Goat anti-Guinea Pig IgG (H+L) 
Secondary Antibody, HRP 
Invitrogen A18769 Goat 
WB 1:2,000 
IHC 1:1,000 
SuperBoost™ Goat anti-Rabbit Poly 
HRP 
Invitrogen B40962 Goat IHC N/A 
SuperBoost™ Goat anti-Mouse Poly 
HRP 
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